Document:

Development Agreement

 Exhibit 10.14 
 DEVELOPMENT AGREEMENT 
 THIS DEVELOPMENT AGREEMENT (this
“Agreement”) is made effective as of March 19, 2008 (the “Effective Date”) and entered into by and between Surgi-Vision, Inc., a Delaware corporation (“SVI”) and Cardiac Pacemakers, Inc.
(“CPI”) (individually, a “Party” and collectively, the “Parties”). 
 WHEREAS, the Parties have entered into a License Agreement (the “License Agreement”) concurrent with this Agreement wherein SVI has granted CPI exclusive rights within the Implantable
Cardiac Field to certain Intellectual Property; 
 WHEREAS, SVI is the sole owner or exclusive licensee of in
the Implantable Cardiac Field of the Surgi-Vision IP; 
 WHEREAS, SVI has previously entered into the Bionics
Agreements with Bionics, pursuant to which Bionics has certain ownership and other exclusive rights to certain of SVI’s Intellectual Property in the field of neuromodulation; 

WHEREAS, CPI is a developer, manufacturer and distributor of medical devices used for treating, diagnosing and managing
heart failure, cardiac rhythm disorders, and co-morbidities thereof, including implantable devices used to treat tachychardia, bradychardia and other heart arrhythmias and heart failure; 

WHEREAS, SVI desires to develop for CPI certain implantable leads for use in CPI cardiac rhythm management and heart
failure products. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the
Parties agree as follows: 
  

	 	1.	 Definitions. 

  

	 	A.	 “Affiliate” of a Person is a Person controlling, controlled by or under common control with the Person specified.
“Controlling”, “controlled” or “control” means owning greater than 50% of the voting equity interests of a Person, either directly or indirectly through one or more intermediaries in which it has such an interest, or
otherwise having the power to direct the management of that Person. 

  

	 	B.	 “Arbitrators” has the meaning ascribed thereto in Section 3(F)(iii). 

 

	 	C.	 “Billabong Patents” means (i) the Patents listed on Exhibit A, and (ii) any claims of any future Patent which
claim and are entitled to claim (in whole but not in part, so long as neither CPI nor any of its Affiliates files any claims in a continuation-in-part Patent which require new matter for support for the primary purpose of avoiding, circumventing,
evading or minimizing its payment obligations to SVI hereunder or pursuant the License Agreement) priority to a Patent covered by the preceding clause (i) (e.g., claims in a continuation-in-part Patent which require new matter

 for support are not Billabong Patents, so long as neither CPI nor any of its
Affiliates files any claims in a continuation-in-part Patent which require new matter for support for the primary purpose of avoiding, circumventing, evading or minimizing its payment obligations to SVI hereunder or pursuant to the Development
Agreement). 
  

	D.	 “Bionics” means Boston Scientific Neuromodulation Corporation (formerly known as Advanced Bionics Corporation), a wholly-owned
indirect subsidiary of Boston Scientific Corporation and an Affiliate of CPI. 

  

	E.	 “Bionics Agreements” means the following agreements: (i) the Bionics Lead Development Agreement, (ii) that certain
Amended and Restated Multiple Advance Secured Convertible Promissory Note dated as of June 30, 2007 made by SVI and payable to Bionics (as may be further amended, restated, supplemented or otherwise modified from time to time), (iii) the
Bionics License Agreement, and (iv) that certain Security Agreement dated as of December 30, 2005 by and between SVI and Bionics (as amended by that certain Omnibus Amendment dated as of June 30, 2007, and as may be further amended,
supplemented, or otherwise modified from time to time). 

  

	F.	 “Bionics Amendment” means that certain Omnibus Amendment No. 2 to the Bionics Lead Development Agreement and Bionics License
Agreement dated as of the date hereof by and between SVI and Bionics. 

  

	G.	 “Bionics Lead Development Agreement” means that certain System and Lead Development and Transfer Agreement dated as of
December 30, 2005, as amended by that certain Amendment No. 1 dated as of May 31, 2006, as further amended by that certain Omnibus Amendment dated June 30, 2007, as further amended by the Bionics Amendment (as may be further
amended, supplemented or otherwise modified from time to time). 

  

	H.	 “Bionics License Agreement” means that certain License Agreement dated as of December 30, 2005, as amended by that certain
Omnibus Amendment dated June 30, 2007, as further amended by the Bionics Amendment (as may be further amended, supplemented or otherwise modified from time to time). 

 

	I.	 “Bionics Reserved IP” means any BSC Solely Invented Development IP and any Joint Development IP that is, at least in part,
conceived or reduced to practice by Bionics (or its employees, agents or consultants). 

  

	J.	 “Brady Lead” has the meaning ascribed thereto in the Project Plan attached as Exhibit A. 

 

	K.	 “BSC Controlled IP” means the Patents included in Development IP. 

  
 2 

	L.	 “BSC Core Product Information” means that core product information proprietary to CPI which is listed on Exhibit C hereto (as may
be updated from time to time by CPI upon notice to SVI). 

  

	M.	 “BSC Solely Invented Development IP” means any Intellectual Property Rights conceived or reduced to practice solely (as between the
Parties) by CPI or its Affiliates (or their respective employees, agents or consultants) that are (i) related to this Agreement, (ii) primarily related to the Field, or (iii) based on CPI’s or its Affiliates’ Confidential
Information. 

  

	N.	 “Change Control Document” has the meaning ascribed thereto in Section 2(C). 

 

	O.	 “Change in Control” means any transaction or series of transactions (whether or not related), including a merger, consolidation,
exchange, sale of equity securities, recapitalization, sale of assets, dissolution or liquidation, pursuant to which any Person or group of Persons (within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended)
acquires (directly or indirectly) (i) equity securities possessing the voting power to elect a majority of a Party’s (or a successor’s) board of directors (or equivalent body) or a majority of the voting equity interests in a Party
(or a successor thereto) or (ii) all or substantially all of the assets of a Party. 

  

	P.	 “Change Request” has the meaning ascribed thereto in Section 2(C). 

 

	Q.	 “Claim” means any allegation, demand, investigation, suit, proceeding, claim, settlement or compromise.

  

	R.	 “Confidential Information” means information which, prior to or during the Term (including pursuant to the Earlier Confidentiality
Agreement) is disclosed or shared by one Party to the other Party or generated or developed by one or both Parties, including information that was disclosed, shared, generated or developed under the Earlier Confidentiality Agreement, that the
non-owning Party has a reasonable basis to believe is confidential to the owning Party or has been marked or orally designated by the owning Party as confidential. 

 

	S.	 “CPR” has the meaning ascribed thereto in Section 3(E)(ii). 

 

	T.	 “Cure Period” has the meaning ascribed thereto in Section 5(C)(i). 

 

	U.	 “Damages” has the meaning ascribed thereto in Section 11(A). 

 

	V.	 “Definitive Agreements” means this Agreement and the License Agreement, collectively. 

  
 3 

	W.	 “Determination Notice” means a notice from CPI to SVI stating that CPI has determined that a New Lead is (or is not) a Royalty
Product or will become (or will not become) a Royalty Product upon the issuance of any allowed claims of any pending application for a Royalty Patent. 

 

	X.	 “Development IP” means, collectively, the BSC Solely Invented Development IP, the SVI Solely Invented Development IP and the Joint
Development IP, in each case that is conceived or reduced to practice during the Term and, unless CPI terminates this Agreement pursuant to Section 5(B) or Section 5(C)(v), a period of two (2) years thereafter. For the
avoidance of any doubt, in no event shall the Development IP include (i) the Royalty Patents, (ii) any Existing Intellectual Property, (iii) any Future Intellectual Property or Joint Intellectual Property conceived and reduced to
practice prior to the Effective Date, or (iv) IPR in and to any Intellectual Property licensed by SVI pursuant to the JHU Agreements. The Parties agree and acknowledge that any Future Intellectual Property conceived or reduced to practice after
the Effective Date may also constitute Development IP. 

  

	Y.	 “Earlier Confidentiality Agreement” means that certain Mutual Nondisclosure Agreement entered into by the Parties on
August 20, 2006, as amended by the First Amendment to the Mutual Nondisclosure Agreement entered into by the Parties on September 5, 2007. 

  

	Z.	 “Effective Date” is defined in the introductory paragraph. 

 

	AA.	 “Existing Intellectual Property” has the meaning ascribed thereto in Section 4.8 of the Bionics Lead Development
Agreement. 

  

	BB.	 “Feasibility Study” and “Feasibility Studies” have the meaning ascribed thereto in Section 2(A)(i).

  

	CC.	 “Field” means the Implantable Cardiac Field and the Neuro Field, collectively. 

 

	DD.	 “Future Intellectual Property” has the meaning ascribed thereto in Section 7.6 of the Bionics Lead Development
Agreement. 

  

	EE.	 “Heart Failure Lead” has the meaning ascribed thereto in the Project Plan attached as Exhibit A.

  

	FF.	 “Indemnified Party” has the meaning ascribed thereto in Section 11(A).  

 

	GG.	 “Indemnifying Party” has the meaning ascribed thereto in Section 11(A). 

 

	HH.	 “Implantable Cardiac Field” means the field of implantable medical leads for all cardiac applications (including nerve stimulation
for intentionally affecting the heart), including implantable leads for cardiac rhythm 

  
 4 

 management, heart failure and defibrillation, and all uses, applications,
research, design, development, manufacturing, and marketing of such implantable leads and all products related to such implantable leads, including but not limited to adaptors and components, for all cardiac applications. 

 

	II.	 “Infringe” means (as applicable, depending on the context of the subject or object of the word Infringe) to infringe,
misappropriate, use or disclose without authorization or otherwise violate Intellectual Property Rights (whether direct, indirect, contributory, inducement or otherwise). The words “Infringement” and “Infringing”
have corresponding meanings. 

  

	JJ.	 “Intellectual Property” means intangible property that is legally protectable, including inventions, improvements, discoveries,
conceptions, algorithms, integrated circuits, ideas, techniques, processes, designs, products, developments, specifications, methods, drawings, diagrams, tooling, models, software programs (including object code, source code and commenting), data,
data analysis, data interpretation, written reports, Know-How, Trade Secrets, Confidential Information, documentation and copyrightable material whether patentable or non-patentable. 

 

	KK.	 “Intellectual Property Rights” or “IPRs” means all rights under or to Intellectual Property.

  

	LL.	 “JHU” means the Johns Hopkins University. 

 

	MM.	 “JHU Agreements” means, collectively, (i) that certain License Agreement by and between SVI and JHU entered into on or around
June 20, 1998, as amended by that certain Amendment to License Agreement dated as of January 15, 2000, and as further amended by that certain Addendum to License Agreement entered into on or around December 7, 2004, as in effect as of
the Effective Date, (ii) that certain License Agreement by and between SVI and JHU entered into on or around December 7, 2006, as in effect as of the Effective Date; (iii) the consent letter dated December 27, 2005 signed by JHU,
(iv) the consent letter dated August 7, 2007 signed by JHU, (v) the letter dated August 7, 2007 signed by Bionics, SVI and JHU, and (vi) the consent letter dated March 19, 2008 signed by SVI and JHU.

  

	NN.	 “Joint Development IP” means any Intellectual Property Rights, other than Royalty Patents, conceived or reduced to practice jointly
by SVI (or its Affiliates, employees, agents or consultants) and CPI or one of its Affiliates (or their respective employees, agents or consultants) that are (i) related to this Agreement, (ii) primarily related to the Field, or
(iii) based on CPI’s or its Affiliates’ Confidential Information. 

  
 5 

	OO.	 “Joint Intellectual Property” has the meaning ascribed thereto in Section 11.1(b) of the Bionics Lead Development
Agreement. 

  

	PP.	 “Key Employees” means (i) [***] and (ii) each other employee, agent, consultant and contractor of SVI who has contributed
to or participated in the conception, creation, development or reduction to practice of any Development IP or Royalty Patent on behalf of SVI provided such Person is an employee, agent, consultant or contractor of SVI on or after the Effective Date.

  

	QQ.	 “Know-How” means all factual knowledge and information that gives a Person the ability to produce or market something that it
otherwise would not have known how to produce or market with the same accuracy or precision, including all formulae, algorithms, processes, procedures, writings, data, protocols, techniques, proposals, designs, ideas, concepts, strategic, research
and development information and related documentation business and other plans, research, inventions, and invention disclosure and all records of the foregoing. 

 

	RR.	 “Licensed Product” means any product in the Implantable Cardiac Field, including but not limited to Royalty Products.

  

	SS.	 “Milestone One” has the meaning ascribed thereto in Section 4(A). 

 

	TT.	 “Milestone Payment” means the payment due by CPI to SVI upon satisfaction of any of the Milestones. 

 

	UU.	 “Milestones” has the meaning ascribed thereto in Section 4. 

 

	VV.	 “Milestone Three” has the meaning ascribed thereto in Section 4(C). 

 

	WW.	 “Milestone Two” has the meaning ascribed thereto in Section 4(B). 

 

	XX.	 “Neuro Field” means the neuromodulation field of the Bionics Lead Development Agreement. For purposes of clarity, the Neuro Field
does not encompass the Implantable Cardiac Field. 

  

	YY.	 “New Lead” means any implantable medical lead developed in connection with the Project Plan. 

 

	ZZ.	 “Opinion” has the meaning ascribed thereto in Section 3(D). 

 

	AAA.	 “Patent” means all classes or types of patents, design patents, utility patents, including issued patents, published and
non-published patent applications (including inventors’ certificates and utility models) in any country or jurisdiction or under any treaty, including all originals, provisionals, substitutions, continuations, continuations-in-part,

 [***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment. 

  
 6 

 divisionals, supplementary protection certificates, renewals, all letters
patent granted thereon, and all reissues, reexaminations, extensions, confirmations, revalidations, registrations, patents of addition and foreign counterparts, as well as industrial design registrations. 

 

	BBB.	 “Person” means an individual, partnership, corporation, business trust, limited liability company, unincorporated association,
trust, joint venture or any other entity or governmental authority 

  

	CCC.	 “Project” means the research and development to be conducted according to this Agreement to develop implantable medical leads.

  

	DDD.	 “Project Manager” has the meaning ascribed thereto in Section 2(B). 

 

	EEE.	 “Prosecution” means prosecution of any proceeding in the United States Patent and Trademark Office or in any other registration
authority in any country, including regarding any application (whether ex parte or inter partes), including interference, reexamination and reissue. 

  

	FFF.	 “Prosecution Costs” has the meaning ascribed thereto in Section 6(A). 

 

	GGG.	 “Prosecution Request” has the meaning ascribed thereto in Section 6(D). 

 

	HHH.	 “Royalty Patent” means (i) a Patent to which SVI has and has granted to CPI exclusive commercial rights in the Implantable
Cardiac Field and which is listed on Exhibit D to the License Agreement, (ii) any claims of any future Patent for which SVI has and has granted to CPI exclusive commercial rights in the Implantable Cardiac Field, which claim and are
entitled to claim (in whole, but not in part) priority to a Patent covered by the preceding clause (i) (e.g., claims in a continuation-in-part Patent which require new matter for support are not Royalty Patents), and (iii) any of the
Billabong Patents to which SVI has and has granted to CPI exclusive commercial rights in the Implantable Cardiac Field. For the avoidance of any doubt, CPI acknowledges and agrees that the following shall not be considered in determining whether SVI
has and has granted to CPI exclusive commercial rights in the Implantable Cardiac Field with respect to any Patent: (a) any lien or security interest in such Patent; (b) any rights retained by JHU under the JHU Agreements; (c) to the
extent the Patent was supported by federal funding obtained by JHU, any rights, conditions and limitations imposed by U.S. law (including any royalty-free nonexclusive license granted to the U.S. government pursuant to U.S. law and any requirement
that products used or sold in the U.S. be manufactured substantially in the U.S.); and (d) any right to author, to publish and to retain or transfer copyright to scientific reports retained by SVI or SVI’s collaborators or granted by SVI
to Third Parties. 

  

	III.	 “Royalty Product” means an implantable lead (alone or in combination with other devices) that if sold by CPI or one of its
Affiliates in the 

  
 7 

	 	 
Implantable Cardiac Field would (absent the License (as defined in the License Agreement)) Infringe a valid and enforceable claim of an issued Royalty Patent. 

 

	JJJ.	 “Royalty Product Dispute” has the meaning ascribed thereto in Section 3. 

 

	KKK.	 “Short Form Registration Statement” means a short-form document suitable for recordation at a local patent office, sufficient to
put persons on notice of the license to Patent rights granted pursuant to the Definitive Agreements. 

  

	LLL.	 “Surgi-Vision IP” means all IPR in and to all Intellectual Property in the Implantable Cardiac Field now or hereinafter owned by or
exclusively licensed to SVI, including the Billabong Patents. 

  

	MMM.	 “SVI Grant-Back Field” means all uses which are simultaneously outside both the (i) field of implantable medical devices, and
(ii) the Field. 

  

	NNN.	 “SVI Solely Invented Development IP” means any Intellectual Property Rights, other than Royalty Patents, conceived or reduced to
practice solely by SVI (or its Affiliates, employees, agents or consultants) that are (i) related to this Agreement, (ii) primarily related to the Field, or (iii) based on CPI’s or its Affiliates’ Confidential Information;
provided, however, that in no event shall SVI Solely Invented Development IP include any Intellectual Property Rights conceived or reduced to practice by SVI (or its Affiliates, employees, agents or consultants) that relate to the System (as
defined in the Bionics Lead Development Agreement), but which do not in any way relate to the Lead (as defined in the Bionics Lead Development Agreement), for which Bionics has not contributed to the conception or design.

  

	OOO.	 “Tachy Lead” has the meaning ascribed thereto in the Project Plan attached as Exhibit A. 

 

	PPP.	 “Technology Transfer” means SVI’s transfer to CPI of all relevant information relating to the use of technology in the
Implantable Cardiac Field, including (i) all information relating to such technology, including research documentation, designs, design drawings, specification, Know-How and test methodology and data for the technology, (ii) all
manufacturing information and Know-How, including manufacturing process details, identification of manufacturing equipment, and descriptions of associated quality control tests, and (iii) training of CPI and CPI Affiliate personnel on product
design and manufacturing. 

  

	QQQ.	 “Term” has the meaning ascribed thereto in Section 5(A). 

 

	RRR.	 “Termination Option” has the meaning ascribed thereto in Section 5(B). 

  
 8 

	 	SSS.	 “Third Party” and “Third Parties” mean one or more Persons other than SVI, CPI and their respective Affiliates.

  

	 	TTT.	 “Third Party Licensor” means any Third Party that has granted a Party a license to Intellectual Property.

  

	 	UUU.	 “Trade Secret” means any Know-How or other information that generally facilitates the production, manufacturing, marketing, or sale
of products or services, increases revenues, or provides an advantage over the competition, is not generally known, and is the subject of reasonable efforts to maintain its confidentiality. 

 

	2.	 Development. 

  

	 	A.	 Feasibility and Development. 

(i)        Feasibility
Studies.      SVI shall perform work to assess the feasibility of its implantable medical lead technology for use in designing and developing each of the three (3) types of leads described in the Project Plan,
attached hereto as Exhibit A. The Parties shall perform the feasibility tasks set forth in Section II of the Project Plan, including the specific experimentation and testing steps, product specifications, protocols, schedules and
assignment of responsibilities required to assess the feasibility of each type of lead (each, a “Feasibility Study” and collectively, the “Feasibility Studies”). A Feasibility Study will only be deemed to have been
successfully completed once CPI has determined, in its sole discretion, that such Feasibility Study has resulted in a lead meeting the feasibility determination components listed in the Project Plan, and has provided SVI with written notice of its
acceptance of such Feasibility Study. 

(ii)        Development.     
 Within sixty (60) days after successful completion of the first of the Feasibility Studies, CPI will provide SVI written notice whether it elects to proceed with the Project or to exercise its right to terminate this Agreement pursuant to
Section 5(B) below. If CPI fails to provide SVI written notice within such 60-day period, CPI shall be deemed to have elected to proceed with the Project. If CPI elects to proceed with the Project, the Parties will move forward with
development under the Project Plan. The Parties shall perform the development tasks set forth in Section III of the Project Plan, including the specific experimentation and testing steps, product specifications, protocols, schedules and
assignment of responsibilities, to accomplish the development of each type of New Lead. Development of a New Lead will only be deemed to have been successfully completed once CPI has determined, in its sole discretion, that such New Lead meets the
relevant product specifications in the Project Plan, and has provided SVI with written notice of its acceptance of such New Lead. 
 (iii)        Technology Transfer.      Upon completion of the development for a New Lead, or upon CPI’s earlier request,
SVI will transfer to CPI all technology (as more specifically listed in Section IV of the Project Plan) useful to enable CPI 

  
 9 

 
and its Affiliates to manufacture, design, and sell the relevant New Lead. Technology Transfer for any New Lead will only be deemed to have been successfully completed once CPI has determined, in
its sole discretion, that such Technology Transfer meets the requirements in the Project Plan, and has provided SVI with written notice of its acceptance of such Technology Transfer. 

 

	B.	 Project Administration. Each of SVI and CPI will appoint a project manager to act on its behalf for the Project (each, a “Project
Manager”) and each Party may replace its Project Manager at any time upon notice to the other Party. SVI’s initial Project Manager will be [***]. CPI’s initial Project Manager will be [***]. The Project Managers will act as
contact persons between the Parties in conducting the Project, and will meet on an as-needed basis as mutually agreed to monitor and discuss the Project’s progress. The Project Manager meetings may take place in person or via telephonic or
other electronic means of communication as the Parties may agree. 

  

	C.	 Amending Project Plan. CPI may, upon reasonable notice to SVI in writing, request reasonable changes to the Project Plan by notifying SVI of
the requested change, including such detail as will allow SVI to evaluate it (a “Change Request”). Within ten (10) business days after SVI’s receipt of a Change Request, SVI will, at its own expense, deliver a document to
CPI that (i) assesses whether and the extent to which the requested change causes an increase or decrease in the costs or time required to perform the Project, and (ii) incorporates a description of the requested changes (a “Change
Control Document”). If CPI accepts the Change Control Document in writing, then the provisions of this Agreement and the Project Plan shall be deemed amended to incorporate such change in accordance with the Change Control Document. If CPI
does not accept the Change Control Document in writing within ten (10) business days after CPI’s receipt of the Change Control Document, CPI shall be deemed to have rejected the Change Control Document. Absent CPI’s acceptance of the
Change Control Document in writing, no change requested by CPI pursuant to the Change Request shall be binding on either SVI or CPI. 

  

	D.	 FDA Approval. SVI will assist CPI, at CPI’s sole expense, in obtaining applicable regulatory and legal approvals for any New Lead
developed under this Agreement or any product in which a New Lead is used, to the extent reasonably requested by CPI. Without limiting the foregoing, if CPI chooses to conduct one or more clinical trials relating to a New Lead or any product in
which a New Lead is used, SVI will provide commercially reasonable cooperation and assistance to CPI, at CPI’s sole expense, in developing protocols relating to the trial and in conducting the trial, if requested by CPI.

 [***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment. 

  
 10 

 3. Royalty Products Disputes. 

 

	 	A.	 Within sixty (60) days after (i) successful completion of a Feasibility Study with respect to a New Lead, (ii) successful completion
of the Technology Transfer relevant to a New Lead, and (iii) receipt of FDA approval for a New Lead, CPI shall deliver to SVI a Determination Notice regarding such New Lead. Notwithstanding the foregoing, any failure by CPI to deliver a
Determination Notice will not constitute a breach of this Agreement (it being understood, however, that any failure by CPI to deliver a timely Determination Notice could result in SVI having additional time to assert that the New Lead is a Royalty
Product in accordance with the procedures of this Section 3 with respect to the applicable Milestone Payment). 

  

	 	B.	 Within ninety (90) days of SVI’s Chief Executive Officer, President or Chief Financial Officer obtaining actual knowledge of
(i) successful completion of a Feasibility Study with respect to a New Lead, (ii) successful completion of the Technology Transfer relevant to a New Lead, or (iii) receipt of FDA approval for a New Lead, in each case where CPI has not
already delivered a Determination Notice to SVI, SVI shall deliver to CPI written notice requesting that CPI deliver a Determination Notice for such New Lead with respect to the applicable Milestone Payment. Within sixty (60) days following
CPI’s receipt of such a request, CPI shall deliver to SVI a Determination Notice regarding such New Lead. Notwithstanding the foregoing, (i) any failure by SVI to deliver a request for Determination Notice will not constitute a breach of
this Agreement (it being understood, however, that any failure by SVI to deliver a timely request for Determination Notice could result in SVI losing the opportunity to claim that a New Lead constitutes a Royalty Product for purposes of the
applicable Milestone Payment), and (ii) to the extent CPI determines that the New Lead is or will become a Royalty Product, SVI need not request any further Determination Notice(s) from CPI with respect to the same New Lead.

  

	 	C.	 To the extent there is any dispute between the Parties as to whether a New Lead constitutes (or will constitute) a Royalty Product (any such dispute
being referred to herein as a “Royalty Product Dispute”), such Royalty Product Dispute shall be exclusively resolved pursuant to the provisions of this Section 3. SVI may deliver to CPI written notice of its intent to
begin a Royalty Product Dispute within, and only within, the following timeframes. For the purposes of clarity, if SVI fails to deliver to CPI written notice of a Royalty Product Dispute within the following timeframes, SVI waives its rights to
challenge CPI’s determination or to otherwise claim that a New Lead constitutes (or will constitute) a Royalty Product for purposes of the applicable Milestone Payment. 

(i)       If CPI has delivered a Determination Notice for a particular
New Lead, SVI’s written notice of any Royalty Product Dispute regarding such New Lead must be 

  
 11 

 delivered to CPI either (x) within thirty (30) days after receiving the applicable
Determination Notice, or (y) within thirty (30) days after issuance of a Royalty Patent with a different allowed claim scope than existed at the time of such Determination Notice (in the case of (y), however, the Royalty Product Dispute
must be limited to such different allowed claim scope). 
 (ii)    If CPI failed to deliver
a Determination Notice for a particular New Lead following a written request from SVI pursuant to Section 3(B), SVI’s written notice of any Royalty Product Dispute regarding such New Lead must be delivered to CPI within ninety
(90) days after such written request was delivered to CPI. 
 (iii)   If CPI did not deliver
a Determination Notice for a particular New Lead and SVI was required to, but did not, deliver to CPI a written request for a Determination Notice pursuant to (and in particular, within the timeframe of) Section 3(B), then SVI waives its
right to claim that such New Lead is a Royalty Product for purposes of the applicable Milestone Payment. 
  

	 	D.	 In the event the Parties are unable to resolve a Royalty Product Dispute informally within forty-five (45) days after delivery of SVI’s
written notice of such Royalty Product Dispute, the Parties shall hire an experienced patent attorney who is knowledgeable in the field of intellectual property law relating to medical devices and who (and whose firm) shall have no current or prior
(within the preceding five year period) business relationships with the Parties or any of their respective Affiliates to offer an opinion, within a reasonable amount of time as mutually agreed upon by the Parties, as to whether the New Lead subject
to the Royalty Product Dispute constitutes a Royalty Product (the “Opinion”). If either Party challenges the Opinion, resolution of the Royalty Product Dispute will proceed as follows under this Section 3. The cost of
such patent attorney shall be shared equally between the Parties. 

  

	 	E.	 No Party hereto may invoke, demand, file or otherwise commence an arbitration pursuant to Section 3(F) until the Parties have completed
a good faith mediation of the applicable Royalty Product Dispute in accordance with the following provisions: 

 (i)     Within thirty (30) days after a Party receives notice from the other Party that such other Party challenges the Opinion, the Parties shall confer to jointly select a
mediator. 
 (ii)    If CPI and SVI cannot agree on a mediator pursuant to
Section 3(E)(i) above, such Parties shall request the International Institute for Conflict Prevention & Resolution (“CPR”) to provide, within ten (10) days of making such request, a list of ten
(10) neutral proposed mediators who are experienced patent attorneys or attorneys with substantial patent litigation experience, in each case who are knowledgeable in the field of intellectual property law relating to the development of medical
devices and who (and 

  
 12 

 
whose firms) shall have no current or prior (within the preceding five year period) business relationships with either of the Parties or any of their respective Affiliates. 

(iii)   CPI and SVI each shall have fifteen (15) days to object to any proposed mediator due to a
conflict of interest or other lack of qualifications, and any proposed mediator to which either CPI or SVI objects shall be removed from the list of proposed mediators provided by CPR. Within a period of five (5) days following the end of such
fifteen (15) day objection period, CPI and SVI will then separately rank the remaining mediators, and deliver such ranking to the other Party, and the highest combined ranked mediator shall be selected. Any such mediation shall be completed
within forty-five (45) days after the date on which the mediator is selected. 
 (iv)   The
cost of such mediator shall be shared equally between the Parties. 
  

	 	F.	 In the event that no agreement is reached by CPI and SVI as to a Royalty Product Dispute following a good faith mediation in accordance with
Section 3(E) above, either CPI or SVI, acting alone, may deliver to the other Party written notice demanding arbitration within twenty (20) days following the completion of such mediation undertaken, in which case the following
provisions shall apply: 

 (i)     CPI and SVI hereby agree to use
their reasonable best efforts to complete such arbitration within one hundred and eighty (180) days of receipt of notice demanding arbitration. 
 (ii)    The arbitration shall be conducted in accordance with the then current CPR Rules for Nonadministered Arbitration, as such rules are modified by this Section 3(F) or
by agreement of CPI and SVI. 
 (iii)   The arbitration shall be conducted in Washington, D.C. by
a panel of three (3) neutral arbitrators (the “Arbitrators”) who shall be experienced patent attorneys or attorneys with substantial patent litigation experience, in each case who are knowledgeable in the field of intellectual
property law relating to the development of medical devices and who (and whose firms) shall have no current or prior (within the preceding five year period) business relationships with either of the Parties or any of their respective Affiliates.
Within fifteen (15) days after receipt of notice demanding arbitration, CPI and SVI shall request CPR to provide, within ten (10) days of making such request, a list of fifteen (15) qualified neutral proposed Arbitrators. 

(iv)   CPI and SVI each shall have fifteen (15) days to object to any proposed Arbitrator due to a
conflict of interest or other lack of qualifications, and any proposed Arbitrator to which either CPI or SVI objects shall be removed from the list of proposed Arbitrators provided by CPR. Within a period of five (5) days following the end of
such fifteen (15) day objection period, CPI and SVI will then separately rank the remaining proposed Arbitrators, and deliver such ranking to the other Party, and the three (3) highest combined ranked proposed Arbitrators shall be selected
to be the Arbitrators. 

  
 13 

 (v)         The
Arbitrators shall apply the substantive laws of the Federal Circuit Court of Appeals as to any Patents involved in the Royalty Product Dispute. 
 (vi)        Discovery shall be limited to document requests, requests for admission and depositions. CPI and SVI each shall be entitled to present expert witness
testimony regarding the issues of whether the New Lead at issue constitutes a Royalty Product pursuant to this Agreement. CPI and SVI each shall, within sixty (60) days after receipt of a written request by the other Party, make a reasonable
search for and provide to the other Party documents reasonably relevant to the issues raised by any claim or counterclaim. CPI, on the one hand, and SVI, on the other hand, each shall be limited to twenty (20) hours of non-expert depositions
and fourteen (14) hours of expert depositions. 

(vii)       CPI and SVI shall be entitled to a hearing and a
post-hearing briefing, the scheduling and length of which shall be determined by the Arbitrators. 
 (viii)      The arbitration of any Royalty Product Dispute pursuant to this Section 3(F) shall be final and binding upon the Parties and judgment upon the
decision may be entered in any court of competent jurisdiction. The Arbitrators shall be entitled to render a determination of the disputed items in any Royalty Product Dispute only and shall not be entitled to award damages or other relief unless
the Arbitrators determine that a Party has acted in bad faith with respect to the Royalty Product Dispute. 
 (ix)        The cost of any arbitration pursuant to this Section 3(F), including the cost of the record or transcripts thereof, if any, administrative
fees, and all other fees involved including reasonable attorneys’ fees incurred by the Party determined by the Arbitrators to be the prevailing Party, shall be borne by the Party determined by the Arbitrators not to be the prevailing Party, or
as otherwise determined by the Arbitrators. 

(x)        Any determinations made pursuant to this
Section 3(F) shall, in the absence of fraud or intentional misconduct, be conclusive for all purposes of this Agreement, and CPI, SVI and any Arbitrators appointed pursuant to Section 3(F) each shall be free from any and all
liability resultant from such. 
 4.       Milestones; Payments. CPI
shall make payments to SVI for development of a Royalty Product in accordance with the milestones identified generally below, and described with more particularity in the Project Plan (the “Milestones”). Notwithstanding
Section 4(A), 4(B) and 4(C) below, a Milestone Payment is due and payable only if (x) the New Lead is a Royalty Product (i.e., covered by an issued Royalty Patent), and (y) the License Agreement is in full force and effect on
the date such Milestone Payment would otherwise become due. If a New Lead that was not a Royalty Product at the time a Milestone Payment otherwise would have been due (as provided below) later becomes a Royalty Product upon issuance of a Royalty
Patent, CPI will retroactively make the applicable Milestone Payment(s) to SVI (provided it has not already made such payment(s)) within forty-five (45) days of final determination that such New Lead is a Royalty Product, pursuant to
Section 3 above. 

  
 14 

	A.	 Milestone One Payment. Within forty-five (45) days after successful completion of the Feasibility Study for a New Lead described in the
Project Plan pursuant to Section 2(A)(i) above (“Milestone One”), CPI will pay to SVI the following amounts: Acceptance of the Brady Lead Feasibility Study - five hundred thousand ($500,000.00) dollars; Acceptance of the
Heart Failure Lead Feasibility Study - four million ($4,000,000.00) dollars; Acceptance of the Tachy Lead Feasibility Study - four million ($4,000,000.00) dollars. 

 

	B.	 Milestone Two Payment. If Milestone One has been achieved with respect to at least one of the Feasibility Studies, and CPI does not exercise
the Termination Option in Section 5(B) below, within forty-five (45) days after successful completion of the first Technology Transfer relevant to a New Lead pursuant to Section 2(A)(iii) above (“Milestone Two”), CPI
will pay SVI five hundred thousand ($500,000.00) dollars. For purposes of clarity, there is only a single Milestone Two payment, even if there is Technology Transfer for all three (3) lead types. 

 

	C.	 Milestone Three Payment. If Milestone Two has been achieved, within forty-five (45) days after receipt of FDA approval, if any, for a New
Lead described in the Project Plan (“Milestone Three”), CPI will pay SVI the following amounts: Brady Lead FDA approval - one million ($1,000,000.00) dollars; Heart Failure Lead FDA approval - five million ($5,000,000.00) dollars;
Tachy Lead FDA approval - five million ($5,000,000.00) dollars. For purposes of clarity, there is only a single Milestone Three payment for each lead type, regardless of FDA approval for multiple lead designs of a single lead type.

  

	D.	 Subject to Section 6(B) of the License Agreement, on and after the date hereof, CPI shall have full control, authority and discretion
over any and all commercialization of Royalty Products, including: (i) all activities relating to clinical trials for Royalty Products, including commencement, termination, patient enrollment, design and timing, (ii) all activities
relating to the manufacture and supply of the Royalty Products; (iii) all marketing, promotion, sales, distribution, import and export activities relating to the Royalty Products; and (iv) all activities relating to any regulatory filings,
registrations, applications and approvals relating to any of the foregoing. As between the Parties, CPI shall own all data, results and all other information arising from any such activities under this Agreement, including all regulatory filings,
registrations, applications and approvals relating to Royalty Products, and all of the foregoing information, documentation and materials shall be considered Confidential Information owned solely by CPI. Other than funding for the activities
required to be performed by SVI, as specifically identified in the Project Plan, as between the Parties the funding of these activities will be by CPI. It is hereby acknowledged and agreed that notwithstanding any and all

  
 15 

 rights granted to CPI herein, or pursuant to the License Agreement, CPI
shall have no obligation whatsoever to exercise such rights. 
  

	 	E.	 After the completion of Milestone One, SVI will remain, and will use its commercially reasonable efforts to cause its employees and contractors to
remain, available for consulting related to the technology and its use in the Implantable Cardiac Field, at commercially reasonable mutually agreed upon terms. 

 

	5.	 Term and Termination. 

  

	 	A.	 Term.     Unless sooner terminated pursuant to this Section 5, the term of this Agreement will begin as of
the Effective Date and shall remain in full force and effect until, and shall expire upon, FDA approval of a lead design for each of the three (3) lead types described in the Project Plan (“Term”). 

 

	 	B.	 Termination Option by CPI.     CPI may, in its sole discretion, elect not to continue with further development and
terminate this Agreement upon written notice to SVI within sixty (60) days after successful completion of the first Feasibility Study pursuant to Section 2(A)(i) above (the “Termination Option”).

  

	 	C.	 Termination for Cause. 

(i)        Termination for Breach. Either Party may
terminate this Agreement for cause on thirty (30) days’ written notice (the “Cure Period”) to the other Party in the event of a breach of any material provision of this Agreement by such other Party; provided that,
during the Cure Period, the breaching Party fails to cure such breach. In the event the noticed breach is incapable of cure, the non-breaching Party may terminate the Agreement immediately upon written notice to the other Party. 

(ii)        Cross Termination. In the event that either
Party terminates the License Agreement for the other Party’s breach of any material provision thereof, the terminating Party, in its sole discretion, may, at that time, terminate this Agreement for cause upon written notice to the other Party.
Termination of this Agreement under this Section 5(C)(ii) shall be effective as of the termination date of the License Agreement. 
 (iii)       Termination for Insolvency. Either Party may terminate this Agreement without notice if the other Party becomes insolvent, makes or has made an
assignment for the benefit of creditors, is the subject of proceedings in voluntary or involuntary bankruptcy instituted on behalf of or against such Party (except for involuntary bankruptcies which are dismissed within sixty (60) days), or has
a receiver or trustee appointed for substantially all of its property. 

  
 16 

 (iv)       No
Prejudice. Any termination by any Party under this Section 5(C) shall be without prejudice to any damages or remedies to which it may be entitled from the other Party. 

(v)        Termination for Change in Control. Upon any
Change in Control of SVI, CPI may, in its sole discretion, terminate this Agreement upon written notice, or, notwithstanding the provisions of Section 16(G), unilaterally amend this Agreement to eliminate any further work on any one or more
specific lead types. SVI shall give CPI prompt written notice of any Change in Control of SVI. 
  

	 	D.	 Effect of Termination. Upon expiration of this Agreement or termination of this Agreement by either Party, (i) each Party will comply
with Section 9(E) (“Return of Information”), and (ii) SVI will effect a Technology Transfer of all Development IP in whatever form or stage of completion the subject of such Technology Transfer may be in at the time of
such expiration or termination. 

  

	 	E.	 Survival. Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or
termination. Without limiting the foregoing, the obligations pursuant to Sections 1, 4(A), 4(B), 4(C) (it is understood, however, that Sections 4(A), 4(B) and 4(C) will survive without prejudice to
any right that CPI may have to damages or offset), 5(D), 5(E), 6, 7, 8, 9, 10, 11, 13, 15 and 16 shall survive termination of this Agreement. Notwithstanding the foregoing,
no claim for breach of warranty or representation under Section 10 may be brought unless it is either (i) brought no later than two years following the latter of the termination or expiration of this Agreement or the License
Agreement, or (ii) brought anytime as a counterclaim or a defense. 

  

	6.	 Intellectual Property Ownership; Licenses.  

 

	 	A.	 Ownership. 

 (i)        Ownership of Development IP. Development IP will be solely owned by CPI (or, to the extent Bionics has rights under the Bionics Agreement, then
solely owned by CPI and Bionics). SVI waives any and all of its rights contained in Section 11.1(b) of the Bionics Lead Development Agreement (“Intellectual Property Re-Transfer and Cross-License”) with respect to any and all
Development IP. 
 (ii)        Restriction on Tail
Period. In no event shall the Development IP include any BSC Solely Invented Development IP, SVI Solely Invented Development IP or Joint Development IP that is conceived and reduced to practice following the Term if CPI terminates this Agreement
pursuant to Section 5(B) or Section 5(C)(v). 
  

	 	B.	 Assignment. SVI hereby assigns and transfers, and shall cause its employees and consultants to assign and transfer, to CPI (or, to the extent

  
 17 

 Bionics has rights under the Bionics Agreement, then jointly to CPI and
Bionics) all right, title, and interest for all countries in and to all Development IP. 
  

	C.	 Further Assurances. Each Party agrees to (and to cause its Affiliates, and its and their employees, agents and consultants to) promptly and
fully disclose in writing to the other Party all Development IP, including all invention disclosure forms or other internal documents as such Party utilizes in the ordinary course of its business to document new inventions. SVI agrees to (and to
cause its Affiliates, and its and their employees, agents and consultants to): (i) execute all documents necessary to effect its assignment of such Development IP, (ii) assist CPI and its Affiliates as set forth in Section 7,
at CPI’s or such Affiliates’ expense, in obtaining foreign and domestic intellectual-property protection on all Development IP and enforcing same, (iii) execute all documents necessary to obtain such intellectual-property protection
in the name of CPI and its Affiliates, and (iv) maintain all information relative to all Development IP, as Confidential Information of CPI and its Affiliates subject to the confidentiality provisions (including permitted disclosures) set forth
in this Agreement. 

  

	D.	 SVI Licenses. CPI hereby grants SVI (i) an exclusive, fully paid, sublicensable, worldwide, perpetual license to all Development IP that is
SVI Solely Invented Development IP for use within the SVI Grant-Back Field, and (ii) a non-exclusive, fully paid, sublicensable, worldwide, perpetual license to all Development IP (with the exception of the Bionics Reserved IP) that is BSC Solely
Invented Development IP or Joint Development IP, for use within the SVI Grant-Back Field. CPI agrees to (and to cause its Affiliates to) execute confirmatory licenses reasonably requested by SVI to evidence SVI’s rights herein set forth.

  

	E.	 CPI License. SVI hereby grants CPI an exclusive, fully paid, sublicensable, worldwide license in the Field for any Surgi-Vision IP developed
or acquired during the Term and a period of two (2) years thereafter, that is not already owned, assigned or licensed to CPI or its Affiliates, provided, that (i) the foregoing license shall terminate in the event CPI exercises the
Termination Option, and (ii) in no event shall the foregoing license include any Intellectual Property Rights conceived or reduced to practice by SVI (or its Affiliates, employees, agents or consultants) that relate to the System (as defined in the
Bionics Lead Development Agreement), but which do not in any way relate to the Lead (as defined in the Bionics Lead Development Agreement), for which Bionics has not contributed to the conception or design. Subject to the foregoing, the Parties
acknowledge that this license is intended to capture Surgi-Vision IP developed or acquired in the time frame described hereinabove which, although related to the Field, is not “primarily” related to the Field. For the avoidance of any
doubt, in no event (x) does this 

  
 18 

 paragraph relate to Royalty Patents, and (y) does the foregoing license affect Bionics’
obligation to make royalty payments to SVI otherwise pursuant to the Bionics License Agreement. 

F.     Recordation. SVI and CPI shall cooperate to prepare a Short Form Registration
Statement and/or confirmatory assignment(s) and license(s) in any countries as to which either Party so desires. Each Party may, at its own expense, record such Short Form Registration Statements and/or confirmatory assignment(s) and license(s).

  

	 	G.	 Joint Development Agreement. This Development Agreement is and is intended to be a “joint development agreement” within the meaning
of 35 U.S.C. § 103(c). 

  

	7.	 Patent Prosecution. 

  

	 	A.	 Costs.     CPI and its Affiliates will pay all Patent Prosecution costs and expenses for all Patents subject to their
sole control, as set forth in Section 7(B) below (“Prosecution Costs”). 

  

	 	B.	 Intellectual Property Protection.   With respect to any BSC Controlled IP, CPI and its Affiliates will jointly control the
Prosecution of all Patents, each at its own expense and with legal counsel of its own choice, and will take such other legal steps as CPI and its Affiliates will determine in their sole discretion to be necessary to protect their rights for all BSC
Controlled IP. For the avoidance of doubt, neither CPI nor its Affiliates will be obligated to pay any Prosecution Costs to protect any Intellectual Property if they determine, in their sole discretion, that those Prosecution Costs outweigh the
likely benefits to CPI or such Affiliate. 

  

	 	C.	 SVI Cooperation.   SVI will cooperate with CPI and its Affiliates in filing, Prosecuting and maintaining Patents and taking such
other legal steps as set forth in this Section 7 and will execute and deliver any documents and instruments in connection therewith which CPI or its Affiliates may request at no additional cost or expense to CPI or such Affiliate.

  

	 	D.	 SVI Intervention.   CPI (or its applicable Affiliate) will provide written notice to SVI prior to abandoning any patent application
or issued Patent that is part of the BSC Controlled IP. If SVI desires to file and Prosecute any patent application, or to pay maintenance fees or annuities to maintain any issued Patent, that CPI or its Affiliates determined was not worthwhile to
protect CPI’s or such Affiliates’ rights, SVI may provide CPI with a reasonable written request to file and Prosecute or maintain such Patent (“Prosecution Request”). If CPI fails to complete the Prosecution Request after
thirty (30) days of receiving the Prosecution Request, then as between the Parties: (i) SVI may independently file and Prosecute the patent application or maintain the issued Patent that was the subject of the

  
 19 

	 	 
Prosecution Request; (ii) SVI will bear all Prosecution Costs with respect to such patent application or issued Patent; (iii) SVI will control the remainder of the Prosecution for the
patent application or the maintenance of the issued Patent that was the subject of the Prosecution Request; and (iv) CPI and its Affiliates will have the right (but not the obligation) to participate in an advisory capacity in such Prosecution.
The Parties acknowledge and agree that any action by SVI pursuant to this Section 7(D) will not confer or convey any ownership rights in the subject Patent to SVI, and will not otherwise adversely affect any of CPI’s or its
Affiliates’ rights in same. 

  

	8.	 Enforcement. 

  

	 	A.	 Notice of Infringement. If either Party learns of any actual, alleged or threatened Infringement of any BSC Controlled IP by a Third Party,
such Party shall promptly notify the other Party and shall provide such other Party with all available evidence of such Infringement. 

  

	 	B.	 Enforcement [***]. As between the Parties, [***] shall have the sole right (but not the obligation), each at its own expense and with legal
counsel of its own choice, to bring suit (or take other appropriate legal action) against any actual, alleged or threatened Infringement of [***] provided, however, that [***] shall have the right (but, subject to Section 11(C)
below, not the obligation) to participate in an advisory capacity only in the institution and prosecution of any such Infringement suit, [***]. 

  

	 	C.	 Join in Action. If either [***] brings any such action or proceeding hereunder, [***] agrees to be joined as party plaintiff if necessary to
prosecute such action or proceeding, and, at [***] expense, to give [***] reasonable assistance and authority to file and prosecute the suit; provided, however, that neither [***] shall be required to transfer any right, title or
interest in or to any property to [***] or any Third Party to confer standing on [***] hereunder. 

  

	 	D.	 Costs. [***] will pay all costs, fees, and expenses associated with an Infringement action they have initiated and prosecuted. [***] will pay
all costs, fees, and expenses associated with [***] participation in an advisory capacity under Section 8(B). 

  

	 	E.	 Recovery. Any recovery obtained in an action initiated and prosecuted solely by [***], and in which [***] does not participate in an advisory
capacity, shall belong to [***]. Any recovery obtained in an action initiated and prosecuted by [***], and in which [***] participates in an advisory capacity, shall be 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant
to a request for confidential treatment. 

  
 20 

 allocated in a fair and equitable manner mutually determined by the Parties.
For purposes of clarity, any recovery pursuant to this section will be net of litigation costs as provided in Section 8(D) above. 
  

	 	F.	 Cooperation. [***] agrees to fully cooperate with [***] in the prosecution of any such suit at no additional expense to [***].

  

	9.	 Confidentiality. 

  

	 	A.	 Ownership of Confidential Information. The Parties agree that (i) all BSC Controlled IP will be deemed to be Confidential Information
owned by CPI (irrespective of which Party generated, development or first shared or disclosed such information), (ii) all BSC Core Product Information generated or developed by CPI, its Affiliates, or a Third Party on behalf of CPI or its
Affiliates will be deemed to be Confidential Information owned by CPI, and (iii) the terms and existence of the Definitive Agreements are Confidential Information owned by both Parties. Except as otherwise expressly provided in this
Section 9, neither Party is subject to the obligations of a “non-owning Party” with respect to Confidential Information that is owned by both Parties. Except as otherwise expressly provided in this Agreement, for all other
Confidential Information, the “owning Party” is deemed to be the disclosing Party. Confidential Information shall remain the property of the owning Party, and the non-owning Party shall not be deemed by virtue of this Agreement or any
access to the owning Party’s Confidential Information to have acquired any right, title or interest in or to any Confidential Information, except the limited right to use such Confidential Information in accordance with the terms of the
Definitive Agreements or other agreements between the Parties or their Affiliates. 

  

	 	B.	 Non-Use and Non-Disclosure. Prior to the commencement of the Term, certain Confidential Information was exchanged between the Parties under
the terms of the Earlier Confidentiality Agreement. Likewise, from time to time during the Term, either Party may make available to the other Party or otherwise generate or develop Confidential Information. The non-owning Party will maintain the
owning Party’s Confidential Information in confidence and will not use such Confidential Information except as reasonably necessary to perform its obligations and exercise its rights under this Agreement or other agreements between the Parties
or their Affiliates. Notwithstanding any provision to the contrary contained in the Bionics Lead Development Agreement, SVI agrees and acknowledges that CPI and its Affiliates may share all of SVI’s Confidential Information with and among each
of their respective Affiliates for use solely within the Field, provided that (i) prior to any such sharing of SVI’s Confidential Information such Affiliates are bound by obligations of confidentiality, non-disclosure and non-use
substantially similar in scope to those in this Agreement and (ii) CPI shall be 

 [***] Indicates
portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

  
 21 

 responsible for any breach of confidentiality, non-disclosure and non-use by
any such Affiliate. Neither Party will disclose the other Party’s Confidential Information without the prior written consent of the other Party, except as permissible in Section 9(D) below or in other agreements between the Parties
or their Affiliates. All Confidential Information will be treated by the non-owning Party with the same care as it would exercise in the handling of its own Confidential Information, but not less than reasonable care. The limitations and
undertakings specified in this Section 9 shall survive termination of this Agreement for a period of five (5) years. 
  

	C.	 Standard Exceptions. The obligations of Sections 9(B), (E) and (F) do not apply to any of the other Party’s
Confidential Information: (i) which, other than the Development IP, is already known by the non-owning Party at the time of the disclosure; (ii) following such information becoming publicly known without the wrongful act or breach of this
Agreement by the non-owning Party; (iii) following such information becoming rightfully received by the non-owning Party from a Third Party without breaching any confidentiality obligation owed by such Third Party to the owning Party;
(iv) following such information becoming approved for release by written authorization of the owning Party; or (v) other than the Development IP, following such information becoming subsequently and independently developed by employees or
representatives of the non-owning Party without knowledge or use of the owning Party’s Confidential Information. The burden of proving the existence of facts which would provide an exception under this Section 9(C) rests with the
non-owning Party. Notwithstanding any provision herein to the contrary, to the extent required under the JHU Agreements, SVI shall be permitted to disclose the terms of this Agreement to JHU. 

 

	D.	 Permitted Disclosures. Each Party may disclose the other Party’s Confidential Information: 

(i)     to the extent reasonably necessary for a Party to prepare, file and Prosecute a Patent
application under this Agreement or other agreements between the Parties or their Affiliates; 

(ii)    to the extent permissible under any other agreements between the Parties or their Affiliates;

 (iii)   to the extent reasonably necessary for a Party to develop or commercialize, directly or
indirectly through one or more licensees, products related to or utilizing Intellectual Property within its allocated (or retained) field of rights pursuant to this Agreement or the Development Agreement; provided that: (a) such
disclosure may include the disclosure of this Agreement’s existence and the scope of any license granted hereunder; (b) prior to making any such disclosure pursuant to this subsection, such Party will, if reasonably practical, take
reasonable steps to limit the scope of such disclosure and its effect on confidentiality; and (c) this subsection will not apply to any BSC Core Product Information owned by CPI; 

  
 22 

 (iv)    to the extent reasonably necessary for the
purposes of this Agreement or other agreements between the Parties, to its respective Affiliates, consultants, agents, advisors, attorneys, outside contractors and clinical investigators, but only if those Persons are bound by obligations of
confidentiality, non-disclosure, and non-use substantially similar in scope to those in this Agreement; provided, such Party shall be responsible for any breaches of confidentiality, non-disclosure and non-use by any such Affiliate,
consultant, agent, advisor, attorney, outside contractor or clinical investigator to whom disclosure is made; 

(v)     in connection with communications to such Party’s stockholders and prospective
investors; provided that unless otherwise agreed between the Parties: (a) such stockholders and prospective investors are subject to obligations of confidentiality no less stringent than those contained herein; and (b) such
disclosure be expressly limited to the existence of this Agreement and the scope of any license granted hereunder; 
 (vi)    to the extent reasonably necessary to enforce this Agreement or other agreements between the Parties or their Affiliates; 

(vii)   to the extent reasonably necessary to comply with a subpoena, court order, or administrative
order. Before complying, the Party subject to such subpoena, court order or administrative order will notify the other Party, allow the other Party a reasonable time to oppose the disclosure, and reasonably cooperate with the other Party’s
efforts to do so; or 
 (viii)  to the extent reasonably necessary to comply with an applicable law,
rule, regulation of any Governmental Authority or securities exchange, including the FDA, the Securities and Exchange Commission and the New York Stock Exchange. Before complying, the Party subject to such law, rule or regulation will notify the
other Party, allow the other Party a reasonable time to seek a protective order (if appropriate), and reasonably cooperate with the other Party’s efforts to do so. 

 

	E.	 Return of Information. Upon termination or expiration of this Agreement for any reason, each Party will return or destroy (at the other
Party’s choice) all Confidential Information owned by such other Party then in its possession and, if applicable, provide a certification of such destruction. 

 

	F.	 Injunctive Relief. Each Party acknowledges and agrees that the breach of this Section 9 would be likely to cause serious and
irreparable harm, the amount of which may be extremely difficult to estimate, thus making any remedy at law or in damages inadequate. Each Party therefore agrees that if the other Party breaches this Section 9 or if such Party has cause
to 

  
 23 

 believe that the other Party intends to or is about to breach such
provisions, then such Party will be entitled to seek injunctive relief enjoining the breach and will have the right to specifically enforce this Agreement and the terms and provisions hereof in addition to any other remedy available at law or in
equity. 
  

	 	G.	 Termination of Earlier Confidentiality Agreement. The Parties agree that the Earlier Confidentiality Agreement will terminate as of the
Effective Date, and that any and all Confidential Information exchanged or disclosed by the Parties pursuant to the Earlier Confidentiality Agreement will be subject solely to the terms of this Section 9 and Section 9 of the
License Agreement. 

  

	10.	 Representations, Warranties and Covenants. 

 

	 	A.	 No Conflicting Agreements.    SVI represents, warrants and covenants that, after giving effect to the Bionics Amendment,
it has not and will not enter into any agreement or commitment or obligation with any Third Party or Affiliate that conflicts in any way with its obligations under this Agreement. CPI represents, warrants and covenants that it has not and will not
enter into any agreement or commitment or obligation with any Third Party or Affiliate that conflicts in any way with its obligations under this Agreement. 

 

	 	B.	 Authority.    Each Party represents and warrants that, as of the Effective Date and after giving effect to the Bionics
Amendment: (i) it has the full right, power, and authority to execute and deliver this Agreement and to perform its terms; (ii) it has taken all required corporate actions to approve and adopt this Agreement; (iii) this Agreement is
enforceable against it according to its terms, subject to bankruptcy, insolvency, and other laws relating to or affecting creditors’ rights and to general equity principles; and (iv) the person or persons executing this Agreement on its
behalf are duly authorized and empowered to do so. 

  

	 	C.	 Sufficiency.    SVI represents and warrants that Exhibit A and Exhibit D to the License Agreement
collectively set forth a true and complete list, as of the Effective Date, of all Patents related to the development of the Licensed Products pursuant to the Development Agreement which are (i) owned or co-owned by SVI, and (ii) licensed
to SVI (complete with the name of the Third Party Licensor of each licensed Patent) in the Implantable Cardiac Field. SVI represents and warrants that all items required to be disclosed pursuant to clause (ii) are licensed exclusively to SVI
and constitute Surgi-Vision IP 

  
 24 

	D.	 Personnel. 

 (i)    Each Party represents, warrants and covenants that all individuals, including employees and consultants, authorized, invited, or otherwise involved by such Party, its employees,
or consultants, to assist in the Project, have or will have a legal obligation to assign, license, or grant an option to license to the relevant Party all their Intellectual Property Rights related to, arising from, or based on the Project.

 (ii)   During the Term and for one (1) year thereafter, SVI will ensure that no Key
Employee will consult, research or develop products for themselves, SVI, any Affiliate of SVI or any Third Party within the Implantable Cardiac Field, other than for or on behalf of SVI pursuant to this Agreement. For the avoidance of doubt, Key
Employees will be free to consult, research and develop products for themselves, SVI, any Affiliate of SVI and any Third Party for all use outside the Implantable Cardiac Field (including, for example, MRI-guided cardiac EP systems). Notwithstanding
the foregoing, the one-year tail period described in the first sentence of this Section 10(D)(ii) shall not apply if CPI terminates this Agreement pursuant to Section 5(B) or Section 5(C)(iv). 

 

	E.	 Non-Infringement. SVI represents and warrants as of the Effective Date that, to its actual knowledge, the New Leads will not Infringe any
Patents, Trade Secrets, copyrights or other Intellectual Property Rights of any Third Party or Affiliate. If, at any time, SVI becomes aware or has reason to believe that the New Leads may Infringe any Patents, Trade Secrets, copyrights or other
Intellectual Property Rights of any Third Party or Affiliate, SVI shall promptly notify CPI in writing of such awareness or belief, describing in reasonable detail the basis for same. 

 

	F.	 Freedom to Operate. SVI represents and warrants that, as of the Effective Date, it has not received and has no knowledge of any Claim by a
Third Party containing any express or implied allegation that SVI, its Third Party Licensors or the Surgi-Vision IP is or may be Infringing any of such Third Party’s Intellectual Property Rights, except that (a) SVI knows of a Third
Party’s attempt to invoke an interference against U.S. 6,904,307, (b) SVI has filed a re-issue with respect to U.S. 6,904,307, and (c) SVI has filed a patent application (application number [***]) attempting to [***]. If, at any time
during the Term, SVI receives or becomes aware of any such Claim, SVI shall promptly notify CPI of such Claim in writing, describing the Claim in reasonable detail (but performing and providing no written analysis regarding the Claim). Provided CPI
has not exercised its Termination Option, upon such notice, CPI may, in its sole discretion, evaluate such Claim to determine whether a license of the Third Party’s Intellectual Property is necessary or desirable, or whether such Third
Party’s Intellectual Property may otherwise have a material effect on the Surgi-Vision IP in the Implantable Cardiac Field. 

 [***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

  
 25 

	 	G.	 Know-How and Trade Secrets. SVI represents, warrants and covenants that: (i) it has taken, and will continue to take, all actions that a
reasonably prudent person would take to maintain its Trade Secrets as confidential and proprietary, and to protect against the loss, theft or unauthorized use of such Trade Secrets; (ii) its Trade Secrets are not in the public domain and have
not been divulged or appropriated to the detriment of SVI; and (iii) SVI’s records do and will continue to include sufficient documentation of the Know-How and Trade Secrets, such as manufacturing and engineering plans, blueprints,
designs, process instructions, formulae, quality assurance protocols and procedures and the like, to enable persons who are reasonably skilled and proficient in the relevant subject matter to continue the same in the ordinary course of business
without unreasonable delay, expense, or reliance on the memory of any individual. 

  

	 	H.	 Disclosure. SVI represents and warrants that in the course of diligence and negotiations leading up to the execution of this Agreement, SVI
has not misrepresented to CPI any material information regarding the Surgi-Vision IP, the technology related thereto, the to-be-developed Development IP and the New Leads. 

 

	 	11.	 Indemnification. 

  

	 	A.	 General Indemnification.    Each Party (the “Indemnifying Party”) will defend, indemnify and hold
harmless the other Party (the “Indemnified Party”) and all of such Party’s Affiliates from and against any and all liabilities, losses, obligations, claims, damages, penalties, causes of action, costs and expenses (including
attorneys’ fees) (collectively “Damages”), to the extent such Damages arise out of any Third Party claim based on allegations that, if true as alleged, would constitute (i) a breach of the representations and warranties
made by it in this Agreement, or (ii) a material breach of its obligations pursuant to this Agreement. 

  

	 	B.	 Indemnification Procedures.    An Indemnifying Party’s duty to indemnify pursuant to Section 13(A) is
subject to the Indemnified Party giving prompt written notice to such Indemnifying Party of any claim against the Indemnified Party covered by the Indemnifying Party’s indemnification obligations hereunder; provided, however, that
a delay in such notice to the Indemnifying Party shall not terminate indemnification obligations hereunder, unless such delay shall have materially impaired the defense of such claim. The Indemnifying Party shall have sole and exclusive control of
the defense of any such claim, including the choice and direction of any legal counsel. The Indemnified Party may not settle or compromise any such claim without the written consent of the Indemnifying Party. 

 

	 	12.	 Insurance. Each Party shall procure and maintain the following insurance during the term of this Agreement: 

  
 26 

	 	A.	 Commercial General Liability Insurance. The insurance shall provide coverage against all claims arising from or relating to the Definitive
Agreements in any manner including, but not limited to, product liability claims and those claims which allege bodily injuries and/or property damage. The liability limits shall not be less than $1,000,000 per occurrence and $1,000,000 in the
aggregate for such claims. 

  

	 	B.	 Excess Liability Insurance. The insurance shall provide excess liability coverage against the risks specified in subsection A above. The
liability limits shall not be less than $1,000,000 per occurrence. 

 Each Party will, upon request, promptly
provide a certificate evidencing that it has insurance coverage as required in this Section 11. Each Party agrees that it will not cancel or materially modify such insurance policies without providing the other Party notice at least
thirty (30) days prior to such cancellation or change becoming effective (it being understood that such notice does not in any way impact a Party’s obligations to maintain insurance coverage as required in this Section 11).

 13.      Disclaimer of
Warranties.        EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY, INCLUDING ANY
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

14.      Exclusivity.        During the Term
of this Agreement, SVI agrees to pursue development efforts with respect to Brady Leads, Tachy Leads and Heart Failure Leads in the Implantable Cardiac Field only with CPI, and not with any Third Party. 

15.      Conflicts with Bionics Lead Development
Agreement.    The Parties agree that, in the event of any conflict between the terms or conditions of this Agreement and the Bionics Lead Development Agreement, this Agreement will control. 

16.      Miscellaneous. 

 

	 	A.	 Notices. Any notice or other communication in connection with this Agreement must be in writing, must be addressed as provided below and will
be deemed delivered when (a) actually delivered in person or by facsimile, provided that delivery is made during normal business hours, (b) three business days have elapsed after deposit in the United States mail, postage prepaid
and registered or certified, return receipt requested, or (c) two business days after sent by nationally recognized overnight receipted courier: 

  
 27 

			
	 To CPI:
	  	
		  	 Cardiac Pacemakers, Inc. c/o

		  	 Boston Scientific Corporation

		  	 One Boston Scientific Place

		  	 Natick, MA 01760-1537

		  	 Attention: Chief Financial Officer

		  	 Phone: 508.650.8000

		  	 Fax: 508.650.8956

		
		  	 with copies to:

		
		  	 Boston Scientific Corporation

		  	 One Boston Scientific Place

		  	 Natick, MA 01760-1537

		  	 Attention: General Counsel

		  	 Phone: 508.650.8000

		  	 Fax: 508.650.8960

		
		  	 and

		
		  	 Cardiac Pacemakers, Inc.

		  	 4100 Hamline Avenue North

		  	 St. Paul, MN 55112

		  	 Attention: Chief Patent Counsel

		  	 Phone: 651.582.7196

		  	 Fax: 651.582.2926

		
	 To SVI:
	  	
		
		  	 Kimble L. Jenkins

		  	 Surgi-Vision, Inc.

		  	 50 North Front Street

		  	 19th Floor

		  	 Memphis, TN 38103

		  	 Phone: 901.531.3236

		  	 Fax: 901.579.4979

		
		  	 with copies to:

		
		  	 John C. Thomas, Jr.

		  	 Surgi-Vision, Inc.

		  	 200 N. Cobb Parkway

		  	 Suite 140

		  	 Marietta, GA 30062-3585

		  	 Phone: 770.514.0077

		  	 Fax: 770.424.8236

  
 28 

			
		  	 and

		
		  	 Oscar L. Thomas

		  	 Bass, Berry & Sims PLC

		  	 100 Peabody Place

		  	 Suite 900

		  	 Memphis, TN 38103

		  	 Phone: 901.543.5905

		  	 Fax: 901.543.5999

 and in any case at such other address as a Party may specify by written notice in accordance with this
Section. All periods of notice will be measured from the date of deemed delivery as provided in this Section. 
  

	B.	 Assignment.    This Agreement shall be binding upon and inure to the benefit of the Parties and their successors and
permitted assigns. Neither this Agreement nor any right or obligation hereunder will be assignable by a Party without the prior written consent of the other Party and any purported assignment without such consent will be void; provided that,
subject to CPI’s exercise of its rights pursuant to Section 5(C)(iv), either Party may, without such prior written consent, assign this Agreement to an Affiliate or in connection with a merger or consolidation (or other similar
transaction) or the sale of all or substantially all of its assets in the realm of its respective field under this Agreement; provided, further, that such Party must give the other Party thirty (30) days prior written notice of
such assignment. Any permitted assignee will assume all obligations of its assignor under this Agreement. No assignment will relieve any Party of responsibility for the performance of any accrued obligation that such Party then has hereunder.

  

	C.	 Affiliates.    To the extent that CPI allows its Affiliates to exercise rights pursuant to this Agreement (including
under a sublicense from CPI), CPI agrees (i) to bind such Affiliates to the confidentiality, use restriction, records/audit, intellectual property enforcement and patent Prosecution provisions of this Agreement and (ii) to be responsible
for any breaches by its Affiliates of such provisions. Notwithstanding anything to the contrary, but subject to the previous sentence, if and when CPI allows its Affiliates to exercise rights pursuant to this Agreement (including under a sublicense
from CPI), CPI may do so under any form of permission or arrangement, whether written, oral or course of conduct, and if done pursuant to a written document irrespective of whether that particular written document contains within its four corners
all of the restrictions and requirements set forth in this Agreement. 

  

	D.	 Force Majeure.    If the performance of this Agreement or any obligations under this Agreement, except the making of
required payments, is 

  
 29 

	 	 
prevented, restricted, or interfered with by reason of fire, flood, earthquakes, explosion, or other casualty, accident, or act of God; strikes or labor disturbances; war, whether declared or
not, or other violence; sabotage; any law, order, proclamation, regulation, ordinance, demand, or requirement of any government agency; or any other event beyond the reasonable control of the Parties, the affected Party, upon giving prompt notice to
the other Party, will be excused from such performance to the extent of such prevention, restriction, or interference. The affected Party will use its reasonable efforts to avoid or remove such cause of non-performance or to limit the impact of the
event on such Party’s performance and will continue performance with the utmost dispatch whenever such causes are removed. 

  

	E.	 Export Controls.    A recipient of technical data or products agrees to comply with all United States Department of
Commerce and other United States export controls. Each Party agrees that, unless prior authorization is obtained from the Office of Export Administration, it will not knowingly ship or transfer technical data covered by this Agreement or any direct
product of such technical data, directly or indirectly, to any country in contravention of any Office of Export Administration requirement. 

  

	F.	 Entire Agreement.    This Agreement and its Exhibits, together with the License Agreement, set forth the entire agreement
between the Parties and supersede all previous agreements and understandings, whether oral or written, between the Parties with respect to the subject matter of this Agreement. 

 

	G.	 Amendment.    This Agreement may not be modified, amended or discharged except as expressly stated in this Agreement or
by a written agreement signed in ink by an authorized representative of each Party. 

  

	H.	 Separability. The provisions of this Agreement will be deemed separable. If any provision in this Agreement will be found or be held to be
invalid or unenforceable in any jurisdiction in which this Agreement is performed, then the meaning of that provision will be construed, to the extent feasible, to render the provision enforceable, and if no feasible interpretation would save such
provision, it will be severed from the remainder of this Agreement that will remain in full force and effect unless the provisions that are invalid or unenforceable substantially impair the value of the entire Agreement to either Party. In such
event, the Parties will use their respective reasonable efforts to negotiate a substitute, valid and enforceable provision that most nearly reflects the Parties’ intent in entering into this Agreement. 

 

	I.	 Waiver. No waiver of any term, provision or condition of this Agreement whether by conduct or otherwise in any one or more instances will be
deemed to be or construed as a further or continuing waiver of any such term, provision or condition or of any other term, provision or condition of this Agreement. 

  
 30 

	J.	 Relationship of Parties. Each of the Parties hereto is an independent contractor and nothing herein will be deemed to constitute the
relationship of partners, joint venturers, nor of principal and agent between the Parties hereto. 

  

	K.	 Counsel/Interpretation. The Parties and their respective counsel have negotiated this Agreement or have had an opportunity to review this
Agreement. The Parties hereto acknowledge and agree that: (a) the rule of construction to the effect that any ambiguities are resolved against the drafting Party will not be employed in the interpretation of this Agreement; and (b) the
terms and provisions of this Agreement will be construed fairly as to all Parties hereto and not in favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement. When used in this
Agreement, the words “including” or “includes” are deemed to be followed by the words “without limitation.” 

  

	L.	 Governing Law. The construction, validity and performance of this Agreement will be governed exclusively by the laws of the State of
Minnesota, U.S.A., without regard to the principles of conflicts of law. Each Party hereby submits itself for the sole purpose of this Agreement and any controversy arising hereunder to the non-exclusive jurisdiction of the federal and state courts
located in the State of Minnesota, and any courts of appeal therefrom, and waives any objection (on the grounds of lack of jurisdiction, venue or forum non conveniens or otherwise) to the exercise of such non-exclusive jurisdiction over it by any
such courts. With the exception of an arbitration pursuant to Section 3 above, any action brought by SVI against CPI in connection with this Agreement, must be instituted in the federal or state courts located in the State of Minnesota.
A Party shall be entitled to seek within such jurisdiction whatever equitable relief it may be entitled to under applicable law. 

  

	M.	 Headings. The article and section headings in this Agreement are inserted for convenience only and will not constitute a part hereof.

  

	N.	 No Third-Party Beneficiary Rights. Except with respect to CPI’s Affiliates and to Persons receiving indemnification under
Section 11, no person not a Party to this Agreement is an intended beneficiary of this Agreement, and no person not a Party to this Agreement will have any right to enforce any term of this Agreement. 

 

	O.	 Compliance with Laws. Each Party will comply in all material respects with all applicable U.S. and foreign statutes, laws, ordinances, rules,
orders and regulations in all actions relating to this Agreement and its performance hereunder. 

  
 31 

	 	P.	 Counterparts. This Agreement may be executed in any number of counterparts each of which will be deemed to be an original but all of which
together will constitute one and the same instrument, and all signatures need not appear on any one counterpart. 

  

	 	Q.	 Effect of Bankruptcy. No proceeding, or result or adjudication of a proceeding, in which either of the Parties is a debtor, defendant or
party seeking an order for its own relief or reorganization, under any foreign, United States or state bankruptcy or insolvency law will (in and of itself) cause a termination of this Agreement or any of the licenses granted under this Agreement.

  

	 	R.	 U.S. Dollars. All Milestone Payments to SVI contemplated in this Agreement shall be made in U.S. Dollars. 

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the Effective Date. 

 

									
	 SURGI-VISION, INC.
	 		 	 CARDIAC PACEMAKERS, INC.

					
	 BY:
	 	 /s/ Kim Jenkins
	 		 	 BY
	 	 /s/ Fred Colen

									
					
	 NAME:
	 	 Kim Jenkins
	 		 	 NAME:
	 	 Fred A. Colen

									
					
	 TITLE:
	 	 Pres
	 		 	 TITLE:
	 	 Executive Vice President,
 Operations and Technology CRM

		 		 		 		 	

  

					
	  

ACKNOWLEDGEMENT BY BIONICS
  

Boston Scientific Neuromodulation Corporation (formerly known as Advanced Bionics Corporation) acknowledges that even though it is not a
party to this Agreement, it hereby agrees that Section 15 of this Agreement shall be binding upon it.

	 		 
	 BY:
	 	 /s/ Michael Onuscheck
	  	 
	 	 
	 NAME: Michael Onuscheck
	  	 
	 	 
	 TITLE:
President
  
	  	 

  
 32 

 EXHIBIT A 
 PROJECT PLAN 
  

	I.	 Definitions 

 Capitalized terms used but not defined herein are as defined in the Development Agreement. 
 Brady Lead: A lead that is used primarily in the right atrium or right ventricle for pacing or sensing and does not deliver high voltage defibrillation therapy. 

Tachy Lead: A lead that delivers high voltage defibrillation therapy and could include pacing and sensing capabilities.

 Heart Failure Lead: A lead that is used primarily in the cardiac veins for pacing and sensing of the left
ventricle and does not deliver high voltage defibrillation therapy. 
  

	II.	 Feasibility Studies 

 A. CPI may use the results of the Feasibility Studies, among other factors, to make a determination as to whether or not CPI will proceed on a path towards commercialization of a potential New Lead that
is a Brady Lead, Tachy Lead or Heart Failure Lead. 
 B. Feasibility Determination Components. [***] 

C. The project manager for the Feasibility Studies is [***]. 
 [***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

  
 33 

 D. The Parties’ goal is to complete the first Feasibility Study, and for CPI to accept
such study pursuant to Section 2(A)(i) of the Development Agreement, within [***]. CPI may initiate other Feasibility Studies during or after the first Feasibility Study. 
 E. During each Feasibility Study, SVI will provide expertise in MRI-safe lead design, prototyping capabilities, and MRI-induced heating test capabilities. Specifically, SVI will have the following
responsibilities: 
 [***] 
 F. CPI will provide expertise specific to the design, testing, manufacture, regulatory approval, and commercialization of implantable CRM leads. CPI will also provide the target specifications for the New
Lead to be designed and embodied in a prototype during the Feasibility Study. 
 G. The Parties will conduct the Feasibility
Studies in four basic phases; provided that it is expected that progress will not always move linearly from phase to phase, rather, it may be an iterative process: 

[***] 
 [***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

  
 34 

	III.	 Development 

 After completion of a Feasibility Study, CPI, in its sole discretion, may decide to initiate technology development and product development projects [***]. 

 

	IV.	 Technology Transfer 

 Transfer from SVI to CPI of all relevant information relating to the use of the technology in the Field relating to each New Lead, including: 

[***] 
 [***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

  
 35 

 EXHIBIT B 

BSC CORE PRODUCT INFORMATION 
 BSC Core Product Information is related to the design, development, manufacture, and commercialization of implantable medical leads for all cardiac applications. This includes but is not limited to:

  

	 	1.	 Design and development documents, methods, and data 

 

	 	a.	 Device specifications 

  

	 	b.	 Assembly drawings, including tolerances 

  

	 	c.	 Material and component specifications, including tolerances 

 

	 	d.	 Material and component supplier capability requirements 

 

	 	e.	 Computational design evaluation methods and results, including FEA methods and results 

 

	 	f.	 Biomechanics parameters used in design evaluation 

  

	 	g.	 Biocompatibility requirements and data 

  

	 	h.	 Design verification and validation methods and results, including fatigue testing and biocompatibility testing 

 

	 	i.	 Pre-clinical and pre-market human clinical trial methods and results j. MRI performance-related testing methods and results

  

	 	2.	 Process development, manufacturing, and process control documents, methods, and data 

 

	 	a.	 Manufacturing instructions and production methods, including connection methodologies and parameters, materials preparation and assembly techniques

  

	 	b.	 Supplier selection process, CPI’s and its Affiliates’ supplier identity and status of supplier relationship 

 

	 	c.	 Supplier material and component qualification methods and results 

 

	 	d.	 Process validation methods and results 

  

	 	e.	 Process control methods and results including sampling plans, test and inspection methods and criteria 

 

	 	3.	 Regulatory submission documents, methods and data 

Any non-public information relating to regulatory approval strategy, and communications with regulatory agencies

 6684061.7 
 fb.us.2472973.47

  
 36Cooperation and Development Agreement

 Exhibit 10.15 
 Cooperation and Development Agreement 
 by and between 

SURGIVISION, INC., a corporation duly organized and existing under the laws of the state 

of Delaware (USA) and having offices at Memphis, Tennessee (USA) 
 (hereinafter referred to as “SURGIVISION”) 
 and 

Siemens Aktiengesellschaft, Healthcare Sector, a corporation duly organized and 

existing under the laws of Germany and having offices at Erlangen, Germany 

(hereinafter referred to as “SIEMENS”) 
 - together hereinafter separately referred to as “PARTY” or jointly as “PARTIES” respectively - 

  
 2 of 40

 Preamble 
 SURGIVISION is a leading company developing, manufacturing and selling devices as well as developing treatment plans for various medical indications, such as deep brain stimulation or cardiac ablation.

 SIEMENS is a leading company in developing, manufacturing and selling Magnetic Resonance (“MR”) Imaging systems,
which are used worldwide for diagnostics of a wide variety of medical indications. MR imaging is free of ionizing radiation and is therefore well-suited for continued supervision of treatment procedures. 

The PARTIES wish to establish a Cooperation and Development Agreement aiming at a combination of the capabilities of Catheter Ablation
and MR imaging in developing a product combination that allows performing the treatment of cardiac arrhythmias by catheter mediated ablation and catheter mediated cardiac electrophysiological mapping procedure under simultaneous MR imaging for
worldwide marketing and sales. The PARTIES agree that this treatment consists of a procedure with the involvement of different medical devices, including catheters and mapping technology as well as MR imaging guidance. The PARTIES intend to develop
an MR workflow with all required components integrated into the special requirements of the MR environment. 
 SIEMENS will be
in charge of development, regulatory release and sales of the software used for MR imaging, localization and visualization of the mapping and ablation catheters, and resulting lesions. SURGIVISION will be in charge of development, regulatory release
and sales of the mapping and ablation catheters as well as any other technology or component required for the application. SURGIVISION will also be in charge of the regulatory release of the different medical devices together as one certified
product. 
 Therefore, having regard to the mutual obligations and covenants contained herein, the PARTIES agree as follows.

 1. Definitions 
  

	1.1.	 “AFFILIATE” shall mean a company in which either of the PARTIES owns or controls, directly or indirectly, more than fifty percent
(50%) of the stock or voting rights. 

  

	1.2.	 “APPLICATION” shall mean the treatment of cardiac arrhythmia by catheter mediated ablation under simultaneous MR imaging and catheter
mediated cardiac electrophysiological mapping under simultaneous MR imaging by using the PRODUCT. In the event the width of an APPLICATION is specified through guidelines of regulatory bodies like SFDA, CE, FDA, such specification shall apply.

  

	1.3.	 “BACKGROUND PATENTS” shall mean patent applications, patents, utility models and other statutory protection with regard to MR SYSTEM,
APPLICATION, CATHETER 

  
 3 of 40

	 	 
TECHNOLOGY, PERIPHERAL TECHNOLOGY, SOFTWARE, INTEGRATION or the PRODUCT under which one PARTY is the owner and/or has the right of determination at any time during the term of this Agreement and
which are not a DEVELOPMENT RESULT. 

  

	1.4.	 “CATHETER TECHNOLOGY” shall mean and comprise the invasive medical devices (e.g. guidewire, catheters) supplied by SURGIVISION for the use
in the PRODUCT and within and in close proximity to an MR SYSTEM and which are defined in more detail in the specifications set forth in ANNEX 2 to this Agreement. ANNEX 2 may upon mutual agreement be amended from time to time. The CATHETER
TECHNOLOGY shall be provided by SURGIVISION as a medical product according to applicable local medical product regulations including, but not limited to, the EU and the USA. 

 

	1.5.	 “CATHETER TECHNOLOGY DEVELOPMENT” shall mean all work and activities related to the development of the CATHETER TECHNOLOGY compatible and
safe for use with an MR SYSTEM and in the PRODUCT. The CATHETER TECHNOLOGY DEVELOPMENT is specified in more detail in ANNEX 1. 

  

	1.6.	 “CHANGE OF CONTROL” means with respect to SURGIVISION, in an event or series of related events: a) a sale of all or substantially all of
SURGIVISION’s assets, voting stock or securities or business relating to this Agreement; b) a merger, reorganization or consolidation involving SURGIVISION in which the stockholders of SURGIVISION immediately prior to such transaction cease to
own collectively a majority of the voting equity securities of the successor entity; or c) a person or group of persons acting in concert acquire fifty percent (50%) or more of the voting equity securities of SURGIVISION, For purposes of
clarity, the term “CHANGE OF CONTROL” does not intend to include (i) an underwritten public offering of SURGIVISION’s common stock pursuant to an effective Registration Statement under the Securities Act of 1933, as amended, or
(ii) any sale of share or capital stock of SURGIVISION, in a single transaction or series of related transactions principally for bona fide equity financing purposes in which SURGIVISION issues new securities to financial and/or venture capital
investors primarily for cash or the cancellation or conversion of indebtedness of SURGIVISION or a combination thereof for the purpose of financing the operations and business of SURGIVISION. 

 

	1.7.	 “DEVELOPMENT WORK” means any and all work to be performed by SIEMENS and/or SURGIVISION in the frame of this Agreement.

  

	1.8.	 “DEVELOPMENT RESULTS” means any and all results, whether patentable or not, in written or oral form, achieved or created by SIEMENS and/or
SURGIVISION in the frame of this Agreement. 

  

	  1.9.	 “DIRECT COMPETITOR” with respect to SIEMENS means an entity that (i) has an MR scanner product line; (ii) currently develops an
MR scanner product line; or (iii) publicly 

  
 4 of 40

	 	 
announces that it is in the process of acquiring or already acquired an MR scanner product line or an entity owning or developing an MR scanner product line. The company Medtronic Inc. or its
affiliates or subsidiaries (hereinafter “Medtronic”) shall not be deemed a DIRECT COMPETITOR under (i) and (ii) with regard to Medtronic’s existing MR scanner product (ODIN, hereinafter “ODIN”), as long as
Medtronic does neither use ODIN in the FIELD, nor develop ODIN for use in the FIELD, nor publicly announces that it intends to use or develop ODIN for use in the FIELD. 

 

	1.10.	 “FIELD” shall mean treatment of cardiac arrhythmia by catheter mediated ablation under simultaneous MR imaging and catheter mediated
cardiac electrophysiological mapping under simultaneous MR imaging. 

  

	1.11.	 “INDIRECT COMPETITOR” in respect to SIEMENS means an entity that is not a DIRECT COMPETITOR but which has a product line that competes
with the MR scanner product line of SIEMENS. 

  

	1.12.	 “INFLUENCE TEST” shall mean the testing process that determine the influence of an external system (CATHETER TECHNOLOGY and PERIPHERAL
TECHNOLOGY) on an SIEMENS MR SYSTEM. 

  

	1.13.	 “INFORMATION” shall mean written and/or oral technical information with regard to MR SYSTEM, APPLICATION, CATHETER TECHNOLOGY, PERIPHERAL
TECHNOLOGY, SOFTWARE, INTEGRATION or the PRODUCT, such information being available to one PARTY at any time during the term of this Agreement and not being a DEVELOPMENT RESULT. It is understood that the INFORMATION of SIEMENS shall be limited to
information available at its Healthcare Magnetic Resonance (H IM MR) Business Unit; INFORMATION does not include BACKGROUND PATENTS. 

  

	1.14.	 “INTEGRATION WORK” shall mean the combination of the CATHETER TECHNOLOGY, MR SYSTEM, SOFTWARE and PERIPHERAL TECHNOLOGY to the PRODUCT, as
well as all work and activities related to such combination and the creation of the PRODUCT. 

  

	1.15.	 “MR SYSTEM” shall mean any applicable SIEMENS MR system. Target MR SYSTEMS for the PRODUCT include the MAGNETOM Verio and the MAGNETOM
Espree. Other MR SYSTEMS might be added after mutual agreement. The MR SYSTEM is currently provided by SIEMENS as a medical product according to applicable local medical product regulations in several countries, including, but not limited to, the
EU, Canada and the USA. 

  

	1.16.	 “PERIPHERAL TECHNOLOGY” means hardware and software required by the user to perform the APPLICATION with the PRODUCT and which is not
already included in CATHETER TECHNOLOGY or SOFTWARE or MR SYSTEM. 

  
 5 of 40

	1.17.	 “PERIPHERAL TECHNOLOGY DEVELOPMENT” shall mean all work and activities related to the development of the PERIPHERAL TECHNOLOGY as
specified in ANNEX 2 SECTIONS 2.7, 2.8, 2.9 AND APPENDIX A, including but not limited to compatibility and safety for use with the MR SYSTEM. 

  

	1.18.	 “PRODUCT” shall mean and comprise a combination of hardware, software and workflow procedures allowing the performance of the APPLICATION
or parts thereof under simultaneous MR imaging, which the PARTIES wish to develop under this Agreement and which is defined in more detail in the specifications set forth in ANNEX 2 to this Agreement. ANNEX 2 may upon mutual agreement be amended
from time to time. The PRODUCT shall be integrated and developed by SURGIVISION as a medical product according to applicable local medical product regulations including, but not limited to the EU and the USA, integrating and combining the SOFTWARE,
MR SYSTEM, CATHETER TECHNOLOGY and PERIPHERAL TECHNOLOGY. 

  

	1.19.	 “SOFTWARE” means software and dedicated MR sequences, which are developed by SIEMENS according to requirement specifications by
SURGIVISION. These specifications are defined in more detail in ANNEX 2 to this Agreement. For the avoidance of doubt, SOFTWARE does not include [***], or any further developments or future versions of [***], but only the dedicated plug in module
dedicated to the workflow of the PRODUCT developed under this Agreement. 

  

	1.20.	 “SOFTWARE DEVELOPMENT WORK” shall mean all work and activities related to the development of the SOFTWARE. 

 

	2.	 Obligations of SIEMENS 

  

	2.1.	 SIEMENS shall perform the SOFTWARE DEVELOPMENT WORK, which shall be based on the specifications contained in ANNEX 2 and shall comprise the efforts
and activities set forth in ANNEX 3 to this Agreement. SIEMENS will - at its sole discretion - perform developments and tests at SIEMENS’ or SIEMENS’ AFFILIATES premises or at hospital sites. 

 

	2.2.	 The SOFTWARE DEVELOPMENT WORK and the release of the SOFTWARE shall be generally carried out in accordance with the time schedule and milestones set
forth in ANNEX 3 to this Agreement. Due to the fact that the release time of the SOFTWARE depends on SIEMENS’ internal software release maps, SIEMENS may need to modify the milestones of the SOFTWARE DEVELOPMENT WORK to reflect any necessities
with regard to such software release map. In that event, SIEMENS shall give written notice to SURGIVISION of any anticipated modification, and the PARTIES shall then negotiate in good faith to appropriately amend the applicable milestone(s) in ANNEX
3. 

  

	2.3.	 SIEMENS shall make available to SURGIVISION INFORMATION for the term of this Agreement insofar as such INFORMATION is necessary for SURGIVISION for
carrying out the INTEGRATION WORK. Disclosure of INFORMATION will be made without charge to SURGIVISION. 

  

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant
to a request for confidential treatment. 

  
 6 of 40

	2.4.	 SIEMENS, insofar as it lawfully may, shall make available to SURGIVISION SIEMENS’ DEVELOPMENT RESULTS achieved during the SOFTWARE DEVELOPMENT
WORK. Prototype versions of the SOFTWARE shall be made available to SURGIVISION according to the milestones set forth in ANNEX 3 and in accordance with Section 3.6. 

Depending on the demands of the INTEGRATION WORK, INFORMATION and DEVELOPMENT RESULTS regarding the SOFTWARE can be
submitted in writing and/or orally. INFORMATION and DEVELOPMENT RESULTS shall be submitted hereunder in the English language. The metric system shall be applied. 
  

	2.5.	 SIEMENS shall be responsible for the regulatory requirements to release the SOFTWARE as a medical device in the EU, Canada and the USA, both for use
under clinical study regulations or for clinical use. Further countries may be added by mutual agreement of the PARTIES. 

 The PARTIES assume that the SOFTWARE will be released as a medical device class 2a in the European Union (CE) and as a class 2 device in Canada and in the USA (FDA). Its intended indication of use is the
tracking of a device within a scanner bore. SIEMENS shall be responsible for the payment of the costs of regulatory approval of the SOFTWARE to the respective authorities. Such cost shall be reimbursed by SURGIVISION and are therefore included in
the milestone payments according to ANNEX 3. If the SOFTWARE cannot be released in the EU as a medical class 2a device or in the USA and Canada as a class 2 device, the PARTIES will jointly consider in good faith how to proceed and how to share
costs. The SOFTWARE shall initially be released for clinical use with the MAGNETOM Espree and MAGNETOM Verio. Other MR scanner platforms will be added as mutually agreed between the PARTIES. 

 

	2.6.	 SIEMENS shall - at SIEMENS reasonable discretion - provide SURGIVISION access to documentation about the SOFTWARE as may be required for regulatory
approval of the PRODUCT for the EU, Canada or the USA. 

  

	2.7.	 When SIEMENS forwards to SURGIVISION parts, components, software - including SOFTWARE or any parts or versions thereof - and other articles for
purposes of the INTEGRATION WORK, SIEMENS shall remain the owner of such material and the intellectual property embodied therein (except as otherwise provided in Section 14.7). 

 

	2.8.	 After productization of the SOFTWARE, SIEMENS shall pay a fix amount of thirty-five-thousand (35,000) US $ per sold licence for the SOFTWARE to
SURGIVISION until a total amount has been paid to SURGIVISION equal to one hundred twenty percent (120%) of the total amount paid by SURGIVISION to SIEMENS pursuant to Section 3.6. If the price SIEMENS expects to receive for the SOFTWARE
in the EU, Canada or the USA upon 

  
 7 of 40

	 	 
execution of this Agreement is more than 10% higher than the price SIEMENS is able to receive at market launch of the SOFTWARE in the respective market, SIEMENS is entitled to detract a
respective percentage from the aforementioned fix amount for the respective market. If - at any time thereafter - the price decreases more than 10%, SIEMENS is entitled to respectively reduce the aforementioned amount every twelve (12) months.
If the price SIEMENS expects to receive for the SOFTWARE in EU, Canada or the USA upon execution of this Agreement is more than 10% lower than the price SIEMENS is able to receive at market launch of the SOFTWARE in the respective market, SIEMENS
shall increase the aforementioned fix amount by a respective percentage for the respective market. If - at any time thereafter - the price increases more than 10%, SIEMENS shall respectively increase the aforementioned amount every twelve
(12) months. 

 Until the total amount to be paid to SURGIVISION has been reached, SIEMENS
will inform SURGIVISION within fourteen (14) days following each calendar quarter about the number of licenses sold by SIEMENS in the past quarter. Thereafter, SURGIVISION will issue a quarterly bill to SIEMENS. SIEMENS shall not be obliged to
effect any payment prior to thirty (30) days following the receipt of the respective invoice. 
 The
obligations under this Section 2.8 of SIEMENS shall end - irrespective, whether the aforementioned total amount had been reached - with the termination of this Agreement according to Sections 15.3.1(i) or 15.3.1 (iii) or 15.3.2(i) or
15.3.2(ii) or 15.3.2 (iv) or 15.3.2 (v) or 15.3.2 (vi) or 17.1. 
 If the Agreement is terminated
according to Section 15.3.1(ii) or 15.3.2(iii) the obligations under this Section 2.8 of SIEMENS to pay SURGIVISION a fix amount based on sold licenses for the SOFTWARE will continue but only until a total amount has been paid to
SURGIVISION equal to the amount actually paid by SURGIVISION to SIEMENS pursuant to Section 3.6. In case the Agreement is terminated according to Section 15.3.1(ii) or 15.3.2(iii) before the Release of the SOFTWARE in the specific market
and if SIEMENS thereafter markets a software that is functionally equivalent to the SOFTWARE within 3 years from the date of termination of the Agreement in the FIELD, which software is substantially based on the DEVELOPMENT RESULTS, the obligations
under this Section 2.8 of SIEMENS to pay SURGIVISION a fix amount based on sold licenses for the SOFTWARE will continue but only until a total amount has been paid to SURGIVISION equal to the amount actually paid by SURGIVISION to SIEMENS
pursuant to Section 3.6. 
 SURGIVISION will have the right, upon reasonable prior notice and reasonable
prior request at SURGIVISION’s sole expense, to designate an independent certified public auditor (hereinafter referred to as “Auditor”) who, upon executing a SIEMENS confidentiality agreement, shall be permitted to enter
SIEMENS’ premises during regular business hours and inspect SIEMENS relevant books and records with respect to ascertaining the amounts due to SURGIVISION under this Section 2.8. The Auditor shall not be allowed to disclose information
obtained during such audits unless such 

  
 8 of 40

 
information relates to SIEMENS’ breach of the payment obligations according to this Section 2.8. Any information disclosed pursuant to the foregoing is strictly confidential and may
only be used to enforce the rights arising from such a breach. Such audits shall be permitted not more than once in a calendar year. Any unpaid amounts that are detected shall be paid by SIEMENS. SURGIVISION shall endeavor to minimize disruption of
SIEMENS’ business activities to the extent reasonably practicable. 
  

	2.9.	 The PARTIES agree that SIEMENS is entitled to provide a maximum of three (3) of its development partners with free licences including updates
and upgrades of the SOFTWARE. With regard to these free licences SIEMENS is not obliged to make payments to SURGIVISION. The PARTIES will agree in good faith whether additional development partners will need to be provided with free licences of the
SOFTWARE or about special conditions for sale for certain customers or development partners. The foregoing shall in no way obligate SURGIVISION to provide SIEMENS’ development partners with CATHETER TECHNOLOGY or PERIPHERAL TECHNOLOGY free of
charge. 

  

	2.10.	 The SOFTWARE remains SIEMENS’ property. 

  

	3.	 Obligations of SURGIVISION 

  

	3.1.	 SURGIVISION shall perform the CATHETER TECHNOLOGY DEVELOPMENT, the PERIPHERAL TECHNOLOGY DEVELOPMENT and the INTEGRATION WORK required to create and
provide the PRODUCT and SURGIVISION shall be responsible for initiation and execution of any procedures in connection with all related regulatory requirements in the EU, Canada and the USA, both for use under clinical study regulations or for
clinical use. Further countries may be added by mutual agreement of the PARTIES. This includes SURGIVISION’s responsibility for the testing of risks and special requirements that arise from the joint clinical use of the MR SYSTEM, the SOFTWARE,
the CATHETER TECHNOLOGY and the PERIPHERAL TECHNOLOGY for use in the PRODUCT for the APPLICATION. The following MR SYSTEMS shall be covered in the INTEGRATION WORK: MAGNETOM Espree and MAGNETOM Verio. 

 

	3.2.	 SURGIVISION shall bear the costs incurred by SURGIVISION for its efforts under or in connection with the CATHETER TECHNOLOGY DEVELOPMENT, the
PERIPHERAL TECHNOLOGY DEVELOPMENT and the INTEGRATION WORK and integration testing as well as the costs of regulatory approval of the PRODUCT. 

  

	3.3.	 SURGIVISION shall comply with all safety notices, risk assessments (if applicable), instruction, etc. as supplied by SIEMENS in the documentation of
the SOFTWARE. 

  

	3.4.	 SURGIVISION, insofar as it lawfully may, shall make available to SIEMENS according to the milestones in ANNEX 3, SURGIVISION’s INFORMATION and
DEVELOPMENT RESULTS insofar as such INFORMATION and DEVELOPMENT RESULTS are 

  
 9 of 40

	 	 
necessary for SIEMENS to carry out the SOFTWARE DEVELOPMENT WORK. The supply of all specifications and the disclosure of INFORMATION and DEVELOPMENT RESULTS is free of charge. INFORMATION and
DEVELOPMENT RESULTS shall be submitted hereunder in the English language. The metric system shall be applied. 

  

	3.5.	 For SURGIVISION to be able to perform the INTEGRATION WORK, SIEMENS will provide engineering (prototype) releases of the SOFTWARE according to
Section 2.4 clearly labeled and specified as “not for clinical use”. SIEMENS shall not safety test these releases, and shall only provide limited documentation and limited risk analysis information to SURGIVISION. SIEMENS does neither
guarantee nor warrant the stability or reliability of this software release. SURGIVISION specifically agrees to use the engineering software at its own risk and to not use for clinical or human diagnosis and/or treatment. SURGIVISION shall
indemnify, defend and hold harmless SIEMENS from any and all claim, liability, damage, loss, or expense imposed upon SIEMENS by third parties due to the use of such engineering (prototype) releases of the SOFTWARE. This provision is not subject to
any limitation of liability under this Agreement. 

  

	3.6.	 SURGIVISION shall pay to SIEMENS an aggregate of two million four hundred seventy six thousand (2,476,000) US$ in installments according to the
milestones reached by SIEMENS in the SOFTWARE DEVELOPMENT WORK and as specified in ANNEX 3. The payment is due thirty (30) days following SURGIVISION’s receipt of a respective invoice issued by SIEMENS. The invoice shall not be issued
prior to the achievement of the respective milestone. 

  

	3.7.	 Upon the conclusion of each of the CATHETER TECHNOLOGY DEVELOPMENT and the PERIPHERAL TECHNOLOGY DEVELOPMENT SURGIVISION shall deliver to SIEMENS
the respective DEVELOPMENT RESULTS for SIEMENS’ performance of the INFLUENCE TEST according to Section 6. Upon completion of the INTEGRATION WORK, SURGIVISION shall deliver to SIEMENS the information about the PRODUCT and the APPLICATION
necessary for risk analysis according to Section 6.2 and fully cooperate with SIEMENS to obtain the risk analysis. 

  

	3.8.	 SURGIVISION shall establish or contract a marketing and sales force to make the CATHETER TECHNOLOGY and PERIPHERAL TECHNOLOGY in the PRODUCT
commercially available to customers in the EU and the US. 

  

	3.9.	 SURGIVISION shall be responsible to perform or have performed by a third party customer training, service and support for the CATHETER TECHNOLOGY
and PERIPHERAL TECHNOLOGY in the PRODUCT. 

  

	3.10.	 For the event SURGIVISION is not able to fulfill Sections 3.8 or 3.9 within 6 months after the completion of the INTEGRATION WORK required to create
and provide the PRODUCT and the receipt of regulatory approval to release the PRODUCT in the applicable market, SIEMENS is herewith granted - and SIEMENS already accepts this grant - a 90-day option free of charge to 

  
 10 of 40

	 	(i)	 terminate the exclusivity according to Section 9.2 in the countries SURGIVISION is not able to fulfill Sections 3.8 or 3.9, or

  

	 	(ii)	 acquire a non-exclusive, sublicensable license in the FIELD for the countries SURGIVISION is not able to fulfil Sections 3.8 or 3.9 to use and
exploit the CATHETER TECHNOLOGY, PERIPHERAL TECHNOLOGY or the PRODUCT, or any and all intellectual property rights related to CATHETER TECHNOLOGY, PERIPHERAL TECHNOLOGY or PRODUCT, to the extent related to the APPLICATION (hereinafter “OPTION
TO LICENSE”). This license is granted upon execution of the OPTION TO LICENSE and already accepted by SIEMENS. 

 If SIEMENS exercises the OPTION TO LICENSE, SIEMENS is additionally granted - and SIEMENS already accepts - a non-exclusive, sublicensable licence in the FIELD for the countries SURGIVISION is not able to
fulfill Sections 3.8 or 3.9 to use any BACKGROUND PATENTS necessary for the use and exploitation of the CATHETER TECHNOLOGY, PERIPHERAL TECHNOLOGY or PRODUCT to the extent related to the APPLICATION. Following the exercise of the OPTION TO LICENSE,
SIEMENS shall no longer be bound by the exclusivity provisions according to Section 9.2 - 9.6 with respect to the countries SURGIVISION failed to fulfill Sections 3.8 or 3.9. 

In return for the aforementioned grant of rights following SIEMENS exercise of the OPTION TO LICENSE, SIEMENS agrees to
pay royalties to SURGIVISION of five percent (5%) of the NET SALES of CATHETER TECHNOLOGY and/or PERIPHERAL TECHNOLOGY, beginning with market launch of such CATHETER TECHNOLOGY and/or PERIPHERAL TECHNOLOGY provided the fact that the CATHETER
TECHNOLOGY and/or PERIPHERAL TECHNOLOGY contains the licensed intellectual property rights of SURGIVISION. As PERIPHERAL TECHNOLOGY may contain different technology components the obligation to pay royalties shall be limited and related to such
components that contain the licensed intellectual property rights of SURGIVISION. Payment of royalties will be limited to the scope of protection of the respective intellectual property rights. “NET SALES” shall mean gross revenue from
sales by SIEMENS and/or SIEMENS’ AFFILIATES, SIEMENS’ distributors, SIEMENS’ sublicensees and other third parties sublicensing the aforementioned rights from SIEMENS, without value-added, consumption or other taxes imposed on the
transaction. If SIEMENS exercises the OPTION TO LICENSE, the fifth paragraph of Section 2.8 shall apply analogously. 
  

	4.	 Communication, Contacts and Meetings 

  

	4.1.	 Each PARTY shall, within one (1) month after this Agreement is signed by the PARTIES, appoint a project manager who will act as a point of
contact during the term of this Agreement. 

  
 11 of 40

	4.2.	 SURGIVISION and SIEMENS shall schedule regular meetings. At these meetings, the project managers appointed as per Section 4.1 and any relevant
other personnel of the PARTIES will review the status of the INTEGRATION WORK, the CATHETER TECHNOLOGY DEVELOPMENT, the PERIPHERAL TECHNOLOGY DEVELOPMENT and the SOFTWARE DEVELOPMENT WORK. The location of the meetings will be alternately appointed
by the PARTIES or the PARTIES will jointly decide where the meeting will be held. Both PARTIES shall cover their own travel costs. 

 In addition, the PARTIES shall keep each other informed on any major progress achieved during the INTEGRATION WORK, the CATHETER TECHNOLOGY DEVELOPMENT, the PERIPHERAL TECHNOLOGY DEVELOPMENT and the
SOFTWARE DEVELOPMENT WORK. Moreover, the PARTIES will inform each other of technical changes to the CATHETER TECHNOLOGY, PERIPHERAL TECHNOLOGY or SOFTWARE that might influence the INTEGRATION WORK or the PRODUCT. 

 

	4.3.	 In the event that either PARTY realizes that the SOFTWARE DEVELOPMENT WORK or the INTEGRATION WORK cannot be efficiently performed according to the
milestones, time schedules and development plans, each PARTY shall immediately inform the other PARTY thereof. The PARTIES shall then review the situation and mutually agree on changes with respect to the further performance of the INTEGRATION WORK
and the SOFTWARE DEVELOPMENT WORK. Section 2.2 shall remain unaffected. 

  

	4.4.	 SIEMENS and SURGIVISION intend to create a scientific advisory board consisting of at least two (2) clinical partners for preference testing of
the PRODUCT. The creation of such advisory board shall be subject to separate agreements between SIEMENS and/or SURGIVISION and the respective clinical partner. The PARTIES agree that, prior to entering into any such agreement with a clinical
partner, the PARTIES will confer with each other and agree on how all technical information and intellectual property rights created under such agreement will be handled (i.e., what rights SIEMENS and SURGIVISION, respectively, will have in and to
such technical information and intellectual property). If the PARTIES cannot agree otherwise, SIEMENS shall at least be granted a non-exclusive, perpetual, worldwide, irrevocable, and unrestricted and royalty free right to use, have used or
sublicense, in the FIELD, any and all technical information and intellectual property rights created by the clinical partner under such agreement that relates to the SOFTWARE. 

The clinical partners will consult SIEMENS and SURGIVISON to a varying degree and level during the term of this Agreement,
from early consulting to customer preference testing. Within the first two months after the execution of this Agreement, SIEMENS and SURGIVISION will agree upon the clinical partners and their level of involvement. At least one of the clinical
partners should be based in Europe, preferably Germany. SIEMENS and SURGIVISON will share travel costs and expenses required for the clinical partners, as long as the clinical partners do not cover their travel costs themselves. It is intended to

  
 12 of 40

 
create regular meetings with the advisory board to obtain differentiated user opinions about the PRODUCT. Depending on the level of involvement of the clinical partner, SIEMENS and SURGIVISON
will provide them with loaned equipment at SIEMENS and SURGIVISlON’s own expenses according to Section 5.9. 
  

	5.	 Loaned Equipment 

  

	5.1.	 SIEMENS shall make available to SURGIVISION on loan medical equipment, items and software products listed in ANNEX 4 (“LOANED EQUIPMENT”)
for the purpose of performing the INTEGRATION WORK. 

  

	5.2.	 Shipment costs of the LOANED EQUIPMENT from SIEMENS premises to SURGIVISION shall be borne by SIEMENS. 

 

	5.3.	 LOANED EQUIPMENT provided by SIEMENS in accordance with Section 5.1 hereinabove shall exclusively be used for the performance of the
INTEGRATION WORK and shall not be handed over or otherwise made available to any third party without SIEMENS’ prior written consent. Insofar as software products are part of the LOANED EQUIPMENT, SURGIVISION shall have the right to use such
software products on the systems or hardware identified in ANNEX 4 for the purpose of performing the DEVELOPMENT WORK. Unless and to the extent expressly authorized by SIEMENS in writing, SURGIVISION shall not be entitled to copy, redevelop,
recompile, change or extract parts of any software products. SIEMENS may at any time replace LOANED EQUIPMENT by other equipment as deemed useful by SIEMENS, provided however, that such other equipment is substantially as suitable as the original
LOANED EQUIPMENT to carry out the INTEGRATION WORK. 

  

	5.4.	 During the term of this agreement SIEMENS shall carry out service and maintenance of the LOANED EQUIPMENT. The incurred costs shall be borne by
SIEMENS. 

  

	5.5.	 No additional costs shall be borne by SIEMENS in connection with the LOANED EQUIPMENT other than those explicitly mentioned herein. In particular,
without limitation, infrastructure costs, such as costs for water or electricity shall be borne by SURGIVISION. 

  

	5.6.	 Within eight (8) weeks upon termination of this Agreement, the LOANED EQUIPMENT shall be returned to SIEMENS by SURGIVISION, unless otherwise
agreed. Shipment costs from SURGIVISION to SIEMENS shall be borne by SURGIVISION. 

  

	5.7.	 Without prejudice to the terms and conditions stated in this Section 5, the loan conditions set forth in ANNEX 5 shall apply with respect to
the loan of LOANED EQUIPMENT. 

  

	5.8.	 SURGIVISION shall provide SIEMENS with prototypes of the CATHETER TECHNOLOGY and PERIPHERAL TECHNOLOGY as defined in the milestones in ANNEX 3 for
performing the SOFTWARE DEVELOPMENT WORK and for performing the 

  
 13 of 40

	 	 
INFLUENCE TEST. The costs incurred shall be borne by SURGIVISION. Shipment costs from SURGIVISION to SIEMENS shall be borne by SURGIVISION. 

 

	5.9.	 The PARTIES agree that equipment of any of the PARTIES which should be loaned to clinical partners is, unless otherwise required by mandatory law,
made available to such partners by SIEMENS or SURGIVISION without additional payment under and in connection with this Agreement and is subject to separate contracts between the respective PARTY and the clinical partner.

  

	6.	 Compatibility Testing and Risk Analysis 

  

	6.1.	 SURGIVISION is responsible for risk analysis and testing of CATHETER TECHNOLOGY and PERIPHERAL TECHNOLOGY. SIEMENS is responsible for the INFLUENCE
TEST and for a SIEMENS risk analysis. 

  

	6.2.	 SURGIVISION is responsible for the INTEGRATION WORK, the testing of all the components after the INTEGRATION WORK and the risk analysis that covers
the complete PRODUCT after the INTEGRATION WORK. The mentioned testing and risk analysis are a subset of the requirements for regulatory approval in the EU, Canada and the USA for use under clinical study regulations or for clinical use (section
3.1). 

  

	6.3.	 SIEMENS shall perform an INFLUENCE TEST of the CATHETER TECHNOLOGY and the PERIPHERAL TECHNOLOGY with the MR SYSTEM. SURGIVISION shall provide
respective components and prototypes of the CATHETER TECHNOLOGY and the PERIPHERAL TECHNOLOGY to SIEMENS as listed in ANNEX 3 and according to the timeline in ANNEX 3. The result of such an INFLUENCE TEST consists of INFORMATION on the proper
functioning of the MR SYSTEM while the CATHETER TECHNOLOGY or the PERIPHERAL TECHNOLOGY is connected or in close proximity to the MR SYSTEM. SIEMENS shall provide the test results in a format that complies to the SIEMENS quality system.

  

	6.4.	 Upon SURGIVISIONs request SIEMENS shall provide SURGIVISION with the results of such an INFLUENCE TEST that SURGIVISION may use for application to
regulatory approval of the PRODUCT. 

  

	6.5.	 However, SIEMENS neither guarantees nor warrants that the result of such an INFLUENCE TEST or the result of the SIEMENS risk analysis will support
or allow for a regulatory approval by the competent authorities. 

  

	6.6.	 SIEMENS shall neither cover any costs related to necessary changes to the CATHETER TECHNOLOGY nor PERIPHERAL TECHNOLOGY nor the PRODUCT as a result
of the INFLUENCE TEST or the SIEMENS risk analysis nor perform or cover the costs for any changes to the MR SYSTEM. 

  
 14 of 40

	6.7.	 SIEMENS shall define a location where the INFLUENCE TEST will be performed (e.g. Europe or USA or China). SURGIVISION shall cover the costs of
shipping the CATHETER TECHNOLOGY and the PERIPHERAL TECHNOLOGY to the defined location and back. 

  

	6.8.	 SURGIVISION shall bear the costs for the INFLUENCE TEST. SIEMENS will perform the INFLUENCE TEST as already reflected in ANNEX 3. The PARTIES may
mutually agree on repeated INFLUENCE TEST not yet reflected in ANNEX 3. The fee for repeated INFLUENCE TESTS will be determined by SIEMENS on a time and material base. In the event INFLUENCE TESTS become necessary in future due to future porting of
SOFTWARE or due to the involvement of other or future MR SYSTEMS involved, SURGIVISION shall bear all costs related to such INFLUENCE TESTS. 

  

	6.9.	 SURGIVISION shall be responsible for the performance of the compatibility tests to ensure that the CATHETER TECHNOLOGY and the PERIPHERAL TECHNOLOGY
is compatible with the MR SYSTEM, meaning the proper functioning of the CATHETER TECHNOLOGY and the PERIPHERAL TECHNOLOGY in close proximity or in connection with the MR SYSTEM and in its intended use in the PRODUCT. SURGIVISION shall bear the costs
of such tests. 

  

	6.10.	 Any payment according to this Section 6 becomes due thirty (30) days following SURGIVISIONS receipt of a respective invoice issued by
SIEMENS. The invoice shall not be issued prior to the performance of the respective INFLUENCE TEST or SIEMENS risk analysis. 

  

	7.	 Completion 

  

	7.1.	 This Agreement is completed, if all SOFTWARE DEVELOPMENT WORK as per ANNEX 2 and all CATHETER TECHNOLOGY DEVELOPMENT, PERIPHERAL TECHNOLOGY
DEVELOPMENT and INTEGRATION WORK - including compatibility testing or risk analysis according to Section 6 - have been successfully completed, SIEMENS obtained the approvals for the SOFTWARE according to Section 2.5 with respect to the
USA, Canada, the EU and any further countries that may be mutually agreed by the PARTIES, SURGIVISION obtained the approvals for the PRODUCT according to Section 3.1 with respect to the USA, Canada, the EU and any further countries that may be
mutually agreed by the PARTIES, and the PRODUCT is clinically released in the USA, Canada, the EU and the aforementioned further countries. 

  

	7.2.	 Later maintenance of SOFTWARE (including service, support, modifications and upgrades) by SIEMENS shall be subject to a separate marketing and sales
agreement according to Section 10. 

  
 15 of 40

	8.	 Changes of Specifications 

  

	8.1.	 The PARTIES will agree in good faith about changes in the SOFTWARE specifications as specified in ANNEX 2 during the SOFTWARE DEVELOPMENT WORK in
accordance with this Section 8. 

  

	8.2.	 SURGIVISION shall inform SIEMENS in writing of any requested changes and/or amendments and specifying the requested changes (hereinafter referred to
as “Change Request”). 

  

	8.3.	 After receiving the Change Request, SIEMENS shall submit a written proposal (e-mail is sufficient) to SURGIVISION describing the work packages,
required resource time, the costs and milestone changes to the SOFTWARE DEVELOPMENT WORK. Costs shall be based upon a calculation rate of four thousand seven hundred (4,700) US$ per man week. Small changes in the specifications (equalling a change
on the time schedule of less than three (3) man days in addition) shall be borne by SIEMENS and shall be covered by the fixed payment from SURGIVISION as specified in Section 3.6. Other changes in the specifications equaling more than
three (3) man days shall be borne by SURGIVISION in accordance with SIEMENS’ proposal or any of its amendments during the negotiation of the Change Request. 

 

	8.4.	 The PARTIES shall mutually agree whether and by whom an analysis of the IP situation in regards to the specific Change Request will be performed
(either by employees of the PARTIES or by an external specialist). If an analysis of the IP situation is mutually agreed upon, SURGIVISON will cover any costs related to the IP Analysis. If SURGIVISION unilaterally decides that the IP Analysis to a
Change Request shall not be performed, section 13.5.2 (ii) applies. 

  

	8.5.	 SIEMENS is not obliged to submit such proposal, if - according to SIEMENS’ reasonable determination - the preparation of such proposal takes
more than one (1) man week or the performance of the Change Request probably causes a delay of the release of the SOFTWARE of more than two (2) men weeks. In these events SIEMENS is additionally entitled to reject the Change Request.

  

	8.6.	 If SURGIVISION accepts the proposal, the Parties will execute a written change order (hereinafter referred to as “Change Order”). The
Change Order will become part of this Agreement. Failure to accept the proposal within five (5) working days following SURGIVISION’s receipt of the proposal shall be deemed as an abandoning of the Change Request, unless the Parties agreed
otherwise. 

  

	9.	 Exclusivity 

  

	9.1.	 Until five (5) years after regulatory approval respectively in the EU, Canada, USA or other applicable region mutually agreed by the PARTIES
(measured from the date of such approval of the PRODUCT for each respective region) SURGIVISION shall not, directly or indirectly through one or more Affiliates or other third parties, sell or offer any device,

  
 16 of 40

	 	 
product or other solution in the FIELD in the respective region that is combined or intended to be used with a non-SIEMENS MR scanner for medical procedures in the FIELD or officially communicate
in the respective market that such device, product or solution that is combined or intended to be used with a non-SIEMENS MR scanner for procedures in the FIELD will be supplied in the respective region in the future. SURGIVISlON’s obligations
in this Section 9.1 with respect to a particular region are subject to the condition that, once the INTEGRATION WORK is completed and the PRODUCT is commercially available in that region, SIEMENS thereafter continues to maintain the commercial
availability of the SOFTWARE in the region. 

  

	9.2.	 Until five (5) years after regulatory approval respectively in the EU, Canada, USA or other applicable region mutually agreed by the PARTIES
(measured from the date of such approval of the PRODUCT for each respective region) SIEMENS shall not, directly or indirectly through one or more Affiliates or other third parties, market or offer SOFTWARE or modified or copied versions of the
SOFTWARE or software that is functionally similar to the SOFTWARE in the respective region with the intention of a combination of the SOFTWARE or modified or copied versions of the SOFTWARE or functionally similar software with non-SURGIVISION
catheters, guidewires and/or other similar devices and products for medical procedures in the FIELD or officially communicate in the respective market that SOFTWARE or modified or copied versions of SOFTWARE or functionally similar software that is
combined or can be used with any such non-SURGIVISION device or product for procedures in the FIELD will be supplied in the respective region in the future. SIEMENS’ obligations in this Section 9.2 with respect to a particular region are
subject to the condition that, once the INTEGRATION WORK is completed and the PRODUCT is commercially available in that region, SURGIVISION thereafter continues to maintain the commercial availability of the CATHETER TECHNOLOGY and the PERIPHERAL
TECHNOLOGY in the region. Notwithstanding the foregoing to the contrary, this Section 9.2 will not apply with respect to SIEMENS’ [***] including further developments to, or future versions of, such base modules.

  

	9.3.	 In case rumours arise in the market that one of the PARTIES may be violating the provisions of Section 9.1 or 9.2, as applicable, such PARTY
shall confirm the exclusivity of the cooperation of the PARTIES in the FIELD with a public statement. 

  

	9.4.	 After the expiration of the exclusivity periods set forth in Sections 9.1 and 9.2, both PARTIES are generally free to enter into relationships with
third parties. However, neither SIEMENS nor SURGIVISION shall enter into a development, sales, marketing or other similar relationship with a third party for a product or system in the FIELD generally excluding or preventing the other PARTY from
sale, marketing or distribution of the PRODUCT, SOFTWARE, CATHETER TECHNOLOGY or PERIPHERAL TECHNOLOGY for a further period of two (2) years beyond the aforementioned exclusivity periods (i.e., neither SURGIVISlON nor SIEMENS may enter into any
such relationship that excludes or prevents the use of SURGIVISION’s CATHETER TECHNOLOGY/PERIPHERAL TECHNOLOGY with SIEMENS’ SOFTWARE/ MR SYSTEM in the FIELD, and vice versa). 

  
 [***]
Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

  
 17 of 40

	9.5.	 The exclusivity may expire or be terminated according to Sections 3.10, 15, 16 and 17. 

 

	9.6.	 The PARTIES acknowledge and understand that the FIELD is [***]. 

 

	10.	 Marketing Support 

 After clinical release of the PRODUCT in the EU, Canada or the USA, the PARTIES shall support each other in marketing activities as seen appropriate by each PARTY. Within nine (9) months before the
commercial availability of the PRODUCT in the EU, Canada or 

  
 [***]
Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

  
 18 of 40

 
the USA, the PARTIES shall enter into negotiations about a separate marketing and sales agreement in form and substance reasonably satisfactory to each PARTY. The PARTIES may agree to use the
SIEMENS sales and distribution channels for sales activities of the CATHETER TECHNOLOGY and PERIPHERAL TECHNOLOGIES. 
  

	11.	 Secrecy 

  

	11.1.	 “Confidential Information” shall mean any information and data, including without limitation, any kind of business, commercial or
technical information and data disclosed between the PARTIES in connection with the execution or performance of this Agreement, irrespective of the medium in which such information or data is embedded, which is-when disclosed in tangible form -
marked “Confidential” by the disclosing PARTY or which is-when disclosed orally or visually - identified as such prior to disclosure and summarized in writing by the disclosing PARTY and said summary is given to the receiving PARTY within
thirty (30) days after such disclosure marked “Confidential”. In case of disagreement, the receiving PARTY must present its objections to the summary in writing within thirty (30) days of receipt. Confidential Information shall
include any copies or abstracts made thereof as well as any apparatus, modules, samples, prototypes or parts thereof. INFORMATION and DEVELOPMENT RESULTS shall be deemed Confidential Information, even if not marked “Confidential”. Each
PARTY will maintain Confidential Information received by the other PARTY in confidence and will use such Confidential Information solely for the purposes of this Agreement, provided, however, that such PARTY may disclose such information to its
officers, AFFILIATES, and those of its employees and subcontractors who need to know it for the purposes of this Agreement. Each PARTY shall impose on its officers, AFFILIATES, and its employees and subcontractors obligations no less stringent than
such PARTY’S confidentiality obligations under this Agreement, and each PARTY will be responsible for any violation of such PARTY’s confidentiality obligations under this Agreement by any of its officers, AFFILIATES, employees or
subcontractors. 

  

	11.2.	 Neither PARTY shall be liable for disclosure and/or any use of Confidential Information as described in Section 11.1 above insofar as such
information 

  

	 	•	 	 is in, or becomes part of, the public domain other than through a breach of this Agreement by such PARTY or such PARTY’s officers, AFFILIATES,
employees or subcontractors; 

  

	 	•	 	 is already known to such PARTY at or before the time it receives the same from the other PARTY or is disclosed to such PARTY by a third party as a
matter of right; 

  

	 	•	 	 is lawfully obtained by the receiving PARTY from a third party without an obligation of confidentiality; 

  
 19 of 40

	 	•	 	 is independently developed by such PARTY without the benefit of Confidential Information received from the other PARTY, unless received under the
exceptions set out in this Section 11.2; 

  

	 	•	 	 is required to be disclosed by any ruling of a governmental or regulatory authority or court or by mandatory law, provided that written notice of
such ruling is given without undue delay to the disclosing PARTY so as to give the disclosing PARTY an opportunity to intervene and further provided that the receiving PARTY uses reasonable efforts to obtain assurance that the Confidential
Information will be treated confidentially; or 

  

	 	•	 	 is disclosed and/or used by such PARTY with the prior written consent of the other PARTY. 

Notwithstanding the above, each PARTY has the right to disclose the other PARTY’S INFORMATION and/or DEVELOPMENT
RESULTS which it received under this Agreement to its customers insofar and to the extent as is customary in the medical device industry (e.g., listing or identifying catheters in the SOFTWARE customer manual). 

 

	12.	 Warranties 

  

	12.1.	 SURGIVISION shall inform SIEMENS without delay in writing of any malfunction or defect of any LOANED EQUIPMENT. SIEMENS shall take appropriate steps
in order to rectify any such malfunction or defect. However, if SIEMENS considers a malfunction or defect to be safety-relevant, SIEMENS shall be entitled to require that SURGIVISION immediately cease the use of affected equipment, components and/or
software, and that SURGIVISION delete all copies of such affected software, in which event SIEMENS shall provide SURGIVISION substitute LOANED EQUIPMENT that is substantially as suitable as the affected LOANED EQUIPMENT to carry out the INTEGRATION
WORK. Further rights against SIEMENS in the event of malfunction or defect of LOANED EQUIPMENT shall be excluded. 

  

	12.2.	 The PARTIES shall undertake reasonable efforts to ensure that their DEVELOPMENT WORK and DEVELOPMENT RESULTS do not infringe intellectual property
rights of any third party. The PARTIES represent and warrant to conduct the DEVELOPMENT WORK in a lawful and professional manner utilizing generally accepted scientific methods and to use reasonable commercial efforts to achieve the tasks of this
Agreement. 

  

	12.3.	 SIEMENS warrants using all reasonable efforts to ensure that the SOFTWARE meets the applicable specifications according to ANNEX 2 and all
applicable regulatory requirements in the countries where SIEMENS uses the SOFTWARE for clinical studies on patients or for clinical use, and to use all reasonable efforts that the respective approvals can be achieved without undue delay.

  
 20 of 40

	12.4.	 SURGIVISION warrants using all reasonable efforts that the CATHETER TECHNOLOGY and the PERIPHERAL TECHNOLOGY meet the specifications according to
the respective Annexes. SURGIVISION warrants performing the INTEGRATION WORK in a manner suitable to create the PRODUCT according to the specifications in ANNEX 2. 

 

	12.5.	 SURGIVISION warrants to use all reasonable efforts to ensure that the PRODUCT meets the specifications in ANNEX 2 and all applicable regulatory
requirements in the countries where SURGIVISION uses the PRODUCT for clinical studies on patients or for clinical use, and to use all reasonable efforts that the respective approvals can be achieved without undue delay. 

 

	12.6.	 The sole obligation of each PARTY with respect to the aforementioned warranties shall be to correct or remedy any defects, errors, malfunctions or
non-compliance with the warranties, especially with the respective specifications defined in the Annexes to this Agreement, (hereinafter “ERRORS”) that might have occurred without undue delay after such ERRORS become known to the PARTY
which provided the respective DEVELOPMENT RESULTS. Following the correction of the ERRORS, the correcting PARTY shall immediately provide the other PARTY with the corrected DEVELOPMENT RESULTS. 

 

	12.7.	 If INFORMATION is incorrect or incomplete, then the PARTY having provided such incorrect or incomplete INFORMATION (the “one PARTY”)
shall, as soon as the one PARTY becomes aware of such error or incompleteness or at the other PARTY’s written request specifying the error or incompleteness, correct the error, if such is possible, or provide the missing INFORMATION to the
extent such INFORMATION is available with the one PARTY. Other than correcting errors or incompleteness as set forth hereinbefore neither PARTY shall assume any warranty or liability with regard to INFORMATION. 

 

	12.8.	 The warranties set forth in this Section 12 shall be the sole warranties under this Agreement, and no other warranties shall apply, in
particular, without limitation, with regard to INFORMATION, SOFTWARE, CATHETER TECHNOLOGY, PERIPHERAL TECHNOLOGY and the LOANED EQUIPMENT. 

  

	13.	 Liability and Indemnification 

  

	13.1.	 SURGIVISION shall in its sole responsibility ensure fulfillment of the instructions received from SIEMENS or its AFFILIATES pertaining to the LOANED
EQUIPMENT and safe handling thereof. SURGIVISION shall indemnify, defend and hold harmless SIEMENS and its AFFILIATES from any and all claims, proceedings, costs, expenses, damages, penalties, and losses (including reasonable attorneys’ fees)
resulting from a nonfulfillment or breach of the aforesaid responsibilities. 

  

	13.2.	 SURGIVISION agrees to defend, indemnify and hold SIEMENS and its AFFILIATES harmless from any and all claims, proceedings, costs, expenses, damages,
penalties, and 

  
 21 of 40

	 	 
losses (including reasonable attorneys’ fees) resulting from SIEMENS use or sale of the PRODUCT (other than the SOFTWARE or MR SYSTEM), CATHETER TECHNOLOGY and/or PERIPHERAL TECHNOLOGY or
SIEMENS or its AFFILIATES use of any of SURGIVISION’s INFORMATION, DEVELOPMENT RESULTS or BACKGROUND PATENTS as permitted under the terms of this Agreement. 

 

	13.3.	 Unless provided otherwise in Section 13.4 below, each PARTY shall be liable for personal injury for which it can be held responsible in
accordance with the applicable legal regulations. It will be liable for physical damage to the other PARTY’S property for which it can be held responsible up to a maximum amount of [***] per incident up to a maximum amount of [***] for all
incidents in the aggregate. 

  

	13.4.	 Except as provided herein, any other claims for damages of the PARTIES shall be excluded, regardless of the legal grounds, in particular, but not
limited to, any claims for damages arising from interruption of business, lost profits or loss of data. The aforesaid limitations and exclusions of liability shall also apply to subcontractors of the PARTIES, including, without limitation,
AFFILIATES. This exclusion shall not apply with regard to Sections 13.1 and 13.2, if this Agreement excludes a limitation of liability or where mandatory law stipulates otherwise under applicable product liability law or in cases of willful
misconduct, of gross negligence or of the non-performance of essential contractual obligations. However, liability for damages arising from non-performance of essential contractual obligations shall be limited to the foreseeable damage typical for
this Agreement except for cases of willful misconduct and gross negligence. 

  

	13.5.	 Indemnification by SIEMENS 

  

	 	13.5.1.	 In the event a third party claims that SURGIVISlON’s use of SIEMENS’ INFORMATION, SIEMENS’ DEVELOPMENT RESULTS or SIEMENS’
BACKGROUND PATENTS infringes the proprietary or intellectual property rights of such third party, SIEMENS shall, at its own choice and as SIEMENS’ sole obligation with regard to such infringement, either procure at its own cost those licenses
necessary for such use of the relevant INFORMATION, DEVELOPMENT RESULTS or BACKGROUND PATENTS as described above, or, with respect to DEVELOPMENT RESULTS, modify the relevant DEVELOPMENT RESULTS in a way that they remain functionally equivalent but
become non-infringing. 

  

	 	13.5.2.	 However, the aforesaid obligations shall not be applicable insofar as the infringement arises in whole or in part out of SURGIVISION’s
responsibility, especially out of - without being limited to - (i) the acts or omissions of SURGIVISION; (ii) compliance with specifications provided by SURGIVISION, where SURGIVSION was informed following the respective IP Analysis according
to ANNEX 3 that the underlying specifications contain risk to infringe intellectual property of third party; (iii) combination or use of the SOFTWARE with other 

  
 [***]
Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

  
 22 of 40

	 	 
software, technology or products except when such combination or use is necessary for the INTEGRATION WORK and specified in an ANNEX to this Agreement, (iv) modification of the SOFTWARE by
persons other than SIEMENS, or (v) with respect to infringement of patents or copyrights resulting from any use of the SOFTWARE outside of the EU, Canada and the US. 

 

	 	13.5.3.	 A prerequisite for the liability of SIEMENS under the terms of Section 13.5.1 shall be that SURGIVISION immediately notifies SIEMENS in writing
of any third party claims on account of the infringement of their property or intellectual property rights, that the alleged infringement is not admitted by SURGIVISION and that SURGIVISION conducts no dispute resolution and reaches no out-of-court
settlements other than with the consent of SIEMENS. 

  

	14.	 DEVELOPMENT RESULTS, INFORMATION and Rights Thereunder 

14.1.   SURGIVISION shall provide SIEMENS with no costs within fifteen (15) days after the signing of
this Agreement with a thorough patent analysis demonstrating the patent protection of its CATHETER TECHNOLOGY and related patents by competitors. The patent analysis shall inter alia -without being limited to - include information about (i) the
current owner/assignee; (ii) any and all of SURGIVISIONS’ existing license agreements, transfer agreements or any other agreements regarding ownership of the patents with third party companies; as well as (iii) information about the
abandoning of any of SURGIVISION’s patents . 
 SIEMENS shall have the right to review the patent analysis
for forty five (45) days. SIEMENS shall have the right to terminate this Agreement without further reasons and without any reimbursement made to SURGIVISION, if SIEMENS comes to the conclusion that information contained in the patent analysis
will prevent a successful or economical reasonable fulfillment of the Agreement; provided, however, that SIEMENS shall reimburse SURGIVISION for any milestone payments already paid by SURGIVISION. SURGIVISION shall provide further clarification on
the patent analysis upon request by SIEMENS. 
 If SURGIVISION intends to abandon a patent relating to its
CATHETER TECHNOLOGY during the term of the Agreement and during the exclusivity periods according to Section 9, SURGIVISION shall inform SIEMENS thereof at least four (4) months prior to the date of the next renewal fee becoming due.

 If SURGIVISION intends selling or transfering any patents relating to SURGIVISION’s CATHETER TECHNOLOGY
during the term of the Agreement and during the exclusivity periods according to Section 9, SURGIVISION shall inform SIEMENS duly in advance about such sale or transfer, at least four (4) weeks prior to the conclusion of the respective
sale or transfer agreement. For the avoidance of any doubt, the foregoing does not apply to the grant of any non-exclusive license in the FIELD or the grant of any license outside the FIELD. 

  
 23 of 40

	14.2.	 Each PARTY shall remain the owner of its INFORMATION, BACKGROUND PATENTS and DEVELOPMENT RESULTS (if applicable), and shall retain the ability to
grant rights, licenses and submit patents at its discretion. 

  

	14.3.	 Each PARTY hereby grants to the other PARTY a non-exclusive, non-transferable, fully paid license in the FIELD to use its INFORMATION, BACKGROUND
PATENTS and DEVELOPMENT RESULTS (if applicable) during the term of this Agreement for the purpose of carrying out the tasks of this Agreement. This license is sublicenseable solely to AFFILIATES of the respective licensee.

  

	14.4.	 Insofar as SURGIVISION needs to make use of SIEMENS’ BACKGROUND PATENTS in the course of the performance of its part of the DEVELOPMENT WORK,
or SURGIVISION needs to make use of such BACKGROUND PATENTS in order to be able to use the DEVELOPMENT RESULTS in accordance with this Agreement, SURGIVISION is herewith granted a non-exclusive, non-transferable right in the FIELD to use such
BACKGROUND PATENTS during the term of this Agreement free of charge for the performance of this Agreement, especially including the development of the PRODUCT and the performance of the INTEGRATION WORK, insofar as the DEVELOPMENT WORK relates to
the creation of the PRODUCT and as long as the PRODUCT is using or including a MR SYSTEM by SIEMENS. This right is sublicensable solely to SURGIVISION AFFILIATES. 

 

	14.5.	 Insofar as SIEMENS needs to make use of SURGIVISION’s BACKGROUND PATENTS in the course of the performance of its part of the DEVELOPMENT WORK,
or SIEMENS needs to make use of such BACKGROUND PATENTS in order to be able to use the DEVELOPMENT RESULTS in accordance with this Agreement, SIEMENS is herewith granted a non-exclusive, non-transferable right in the FIELD to use such BACKGROUND
PATENTS during the term of this Agreement free of charge for the performance of this Agreement, especially the development of the SOFTWARE insofar as the DEVELOPMENT WORK relates to the creation of the PRODUCT and as long as the PRODUCT is using or
including SURGIVISION’s CATHETER TECHNOLOGY and PERIPHERAL TECHNOLOGY. This right is sublicenseable solely to SIEMENS AFFILIATES. 

  

	14.6.	 Each PARTY shall be the sole owner of all rights and title to DEVELOPMENT RESULTS solely created during the execution of the DEVELOPMENT WORK in the
course of this Agreement. For the avoidance of any doubt, any DEVELOPMENT RESULTS solely created by SURGIVISION that consist of software shall be solely owned by SURGIVISION, any DEVELOPMENT RESULTS solely created by SIEMENS that consist of catheter
technology shall be solely owned by SIEMENS. 

  
 24 of 40

	14.7.	 DEVELOPMENT RESULTS - including any and all rights contained therein – created jointly under this Agreement shall be jointly owned by both
PARTIES. Any PARTY shall be free to use such DEVELOPMENT RESULTS as if they were solely created by such PARTY. Section 9 shall be applied. For such joint DEVELOPMENT RESULTS which are eligible for statutory protection, the PARTIES will agree
upon the details for filing for such protection. For joint statutory protection rights each PARTY grants the other PARTY the non-exclusive, non-transferable, sublicenseable and fully paid right to use it at its own discretion.

 For the avoidance of doubt, SOFTWARE shall not be regarded as a joint development but a sole
development by SIEMENS, even if and insofar SOFTWARE is based on specifications provided by SURGIVISION. For the avoidance of any doubt, any other DEVELOPMENT RESULTS jointly created by SIEMENS and SURGIVISION that consist of software shall be
jointly owned by SIEMENS and SURGIVISION. 
  

	14.8.	 Each PARTY hereby already grants to the other PARTY - and the other PARTY already accepts such grant - the non-exclusive, non-transferable and fully
paid license in the FIELD to use and have used the other PARTY’s INFORMATION, BACKGROUND PATENTS and DEVELOPMENT RESULTS during the exclusivity periods according to Section 9 as far as this is necessary for 

	 	(i)	 SIEMENS’ sales of the SOFTWARE for the PRODUCT in each region in which the PRODUCT has received regulatory approval and has been clinically
released, and 

	 	(ii)	 SURGIVISION’s sales of CATHETER TECHNOLOGY or PERIPHERAL TECHNOLOGY for the PRODUCT in each region in which the PRODUCT has received regulatory
approval and has been clinically released. 

 Each PARTY hereby already grants to the other
PARTY - and the other PARTY already accepts such grant - the non-exclusive, non-transferable and fully paid license in the FIELD to use and have used the other PARTY’s INFORMATION, BACKROUND PATENTS and DEVELOPMENT RESULTS following expiration
of the exclusivity periods according to Section 9 as far as this is necessary for 

	 	(i)	 SIEMENS’ sales of the SOFTWARE for the PRODUCT in each region in which the PRODUCT has received regulatory approval, as such SOFTWARE exists as
of the expiration of the exclusivity periods according to Section 9; and 

	 	(ii)	 SURGIVISION’s sales of the CATHETER TECHNOLOGY or PERIPHERAL TECHNOLOGY for the PRODUCT in each region in which the PRODUCT has received
regulatory approval, as such CATHETER TECHNOLOGY or PERIPHERAL TECHNOLOGY exists as of the expiration of the exclusivity periods according to Section 9. 

For the avoidance of doubt, the foregoing license will not permit a PARTY to use or have used the other PARTY’s
INFORMATION, BACKGROUND RIGHTS or DEVELOPMENT RESULTS for any change, modification or improvement to the SOFTWARE or CATHETER TECHNOLOGY or PERIPHERAL TECHNOLOGY, as applicable, following expiration of the exclusivity periods according to
Section 9. 

  
 25 of 40

 The licenses granted under this Section 14.8 shall be sublicensable
solely to AFFILIATES of the respective licensee. 
 Any further regulations shall be agreed upon in the separate
marketing and sales agreement according to Section 10. 
  

	15.	 Term and Termination 

  

	15.1.	 This Agreement shall become effective on the date it is signed by both PARTIES.

  

	15.2.	 This Agreement (unless terminated earlier under a relevant provision set forth in this Agreement)
shall terminate thirty (30) days after successful completion as per Section 7. 

  

	15.3.	 

	15.3.1	 This Agreement may be terminated by SURGIVISION without reimbursement to SIEMENS at any time by giving not less than four weeks’ prior written
notice to SIEMENS 

  

	 	(i)	 if SIEMENS is declared bankrupt or otherwise cannot fulfill its financial obligations; 

 

	 	(ii)	 if SIEMENS substantially defaults in the performance of this Agreement and does not remedy the default within 4 weeks after receipt of a relevant
request of SURGIVISION; 

  

	 	(iii)	 if SURGIVISION reasonably comes to the conclusion that [***], the tasks of this Agreement cannot be carried out at all or would not be economically
reasonable; provided, however, that before SURGIVISION may exercise this termination right (i.e., giving written notice of termination pursuant to this provision), SURGIVISION must have (1) notified SIEMENS in writing of SURGlVISlON’s
technical, market or economic concerns and (2) exercised commercially reasonable efforts to work with SIEMENS to address or resolve those concerns, [***]; 

 

	15.3.2	 This Agreement may be terminated by SIEMENS without reimbursement to SURGIVISION at any time by giving not less than four weeks prior written notice
to SURGIVISION 

  

	 	(i)	 if SURGIVISION is declared bankrupt or otherwise cannot fulfill its financial obligations; 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant
to a request for confidential treatment. 

  
 26 of 40

 (ii)  if SURGIVISION substantially defaults in the performance of
this Agreement and does not remedy the default within four (4) weeks after receipt of a relevant request of SIEMENS; 
 (iii)  if SIEMENS reasonably comes to the conclusion that due to [***], the tasks of this Agreement cannot be carried out at all or would not be economically reasonable; provided, however, that
before SIEMENS may exercise this termination right (i.e., giving written notice of termination pursuant to this provision), SIEMENS must have (1) notified SURGIVISION in writing of SIEMENS’ technical, market or economic concerns and (2)
exercised commercially reasonable efforts to work with SURGIVISION to address or resolve those concerns, [***]; 

(iv)  if SURGIVISION knowingly provides wrong or misleading information to SIEMENS according to
Section 14.1 or purposefully omits information relevant for the FIELD or the PRODUCT that would prevent SIEMENS from making an informed decision according to Section 14.1; 

(v)  if SURGIVISION sells or transfers any of its patents relating to its CATHETER TECHNOLOGY or PERIPHERAL
TECHNOLOGY, as contemplated in Section 14.1, without the prior consent of SIEMENS; 
 (vi)  If the
CATHETER TECHNOLOGY is not completely developed on May 1st, 2010, as defined in ANNEX 3, and therefore the INTEGRATION WORK cannot be completed. 
  

	15.4.	 Except as expressly provided to the contrary in this Agreement, Sections 2.5, 2.7, 2.8, 3.2, 3.3, 3.6., 3.10, 9, 10, 11, 13, 14, 15, 16, 17.2, 17.3.
17.4, 18 and 19 shall survive any termination of this Agreement; provided, however, that Sections 2.5, 3.2 and 3.6 shall survive only to the extent of any obligation accruing prior to termination. During the exclusivity periods according to
Section 9, Section 15.3 (other than 15.3.1(iii) and 15.3.2(iii)) shall apply analogously with regard to the termination of the exclusivity. 

  

	15.5.	 In the event this Agreement is terminated prior to the expiration of its term according to Section 15.2, (i) Section 9 shall not
survive the termination of this Agreement with respect to any region in which the PRODUCT has not received regulatory approval and been clinically released as of the date of termination, and (ii) Section 14.8 shall survive the termination
of this Agreement only for any region in which the PRODUCT has received regulatory approval and been clinically released as of the date of termination. 

 

	15.6.	 In case of termination of this Agreement according to Sections 15.3.1 (iii) or 15.3.2 (ii) SURGIVISION shall pay SIEMENS the actual costs
accumulated after the last milestone payment. Costs include actual costs regarding SOFTWARE DEVELOPMENT WORK which are accumulated after the last milestone payment, additional SOFTWARE DEVELOPMENT WORK reimbursed according to Section 8.6, as
well as other additional actual costs, if any, incurred by SIEMENS in the USA caused by the termination of this Agreement. SIEMENS will use all reasonable efforts to keep additional costs as low as possible. In case of termination of this Agreement
according to Sections 15.3.1(i) or 15.3.1(ii) or 15.3.2(iii) SURGIVISION shall not be obliged to pay SIEMENS any upcoming milestone payments for the SOFTWARE DEVELOPMENT WORK according to ANNEX 3. 

  
 [***]
Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

  
 27 of 40

	16.	 Beneficial interest in case of Insolvency of SURGIVISION 

 

	16.1.	 Subject to the terms of Section 16.2 below, SURGIVISION already grants - and SIEMENS accepts this grant - a beneficial interest
(“NieBbrauch”) in the FIELD with regard to the rights and title to the CATHETER TECHNOLOGY, the PERIPHERAL TECHNOLOGY, SURGIVISION’s DEVELOPMENT RESULTS and the PRODUCT, including any BACKGROUND PATENTS in the FIELD necessary
for the use and exploitation of the aforementioned rights and titles with respect to the APPLICATION. For the avoidance of doubt, this beneficial interest shall be a right of use and shall not convey to SIEMENS title to any of SURGIVISION’s
CATHETER TECHNOLOGY, PERIPHERAL TECHNOLOGY, DEVELOPMENT RESULTS or BACKGROUND PATENTS. 

  

	16.2	 This beneficial interest is granted to secure SIEMENS’ ability to use the CATHETER TECHNOLOGY, the PERIPHERAL TECHNOLOGY, SURGIVISION’s
DEVELOPMENT RESULTS and the PRODUCT, including any BACKGROUND PATENTS, in the FIELD for SIEMENS’ purposes with regard to sale, marketing and distribution of the PRODUCT. SIEMENS’ shall only be entitled to exercise this beneficial interest,
if SURGIVISION becomes subject to an insolvency proceeding (other than an involuntary insolvency proceeding against SURGIVISION that is dismissed within ninety (90) days). 

 

	16.3	 In the event that SIEMENS becomes entitled to exercise the beneficial interest according to Section 16.2, the provision of the second paragraph of
Section 17.3 shall apply analogously. SIEMENS shall no longer be bound by the exclusivity provisions according to Section 9. 

  

	17.	 Change of Control 

  

	17.1.	 If SURGIVISION obligates itself with respect to a CHANGE of CONTROL with a third party that is an INDIRECT COMPETITOR of SIEMENS, the PARTIES will
discuss in good faith within thirty (30) days after such CHANGE of CONTROL is publicly announced, how such CHANGE of CONTROL would impact the relationship contemplated by this Agreement, including whether SURGIVISION or such INDIRECT COMPETITOR
will terminate this AGREEMENT after the closing of such CHANGE OF CONTROL transaction. SIEMENS shall be entitled to terminate this Agreement within a period of thirty (30) days following the receipt of such a notification and discussion if it
is not reasonably assured that such CHANGE of CONTROL will not adversely affect the prospects for commercial success of the transactions contemplated by this Agreement. With respect to a CHANGE of CONTROL involving a DIRECT COMPETITOR, SIEMENS shall
be entitled to terminate this Agreement within a period of thirty (30) days following the receipt of such a notification at its own discretion. 

  
 28 of 40

	17.2.	 In case of termination of this Agreement by SURGIVISION following a CHANGE OF CONTROL involving a
DIRECT COMPETITOR or INDIRECT COMPETITOR prior to the regular termination of this Agreement (other than an earlier termination permitted under Section 15.3.1(i) and 15.3.1(ii)), SURGIVISION shall pay SIEMENS the actual costs accumulated after
the last milestone payment. Costs include actual costs regarding SOFTWARE DEVELOPMENT WORK which are accumulated after the last milestone payment, additional SOFTWARE DEVELOPMENT WORK reimbursed according to Section 8.6, as well as other
additional actual costs, if any, incurred by SIEMENS in the USA caused by the termination of this Agreement. 

  

	17.3.	 For the event of a CHANGE OF CONTROL involving a DIRECT COMPETITOR during the term of this Agreement
or during the exclusivity period according to Section 9, SIEMENS is herewith granted - and SIEMENS accepts this grant - a 90-day option - starting with the closing of the transaction or SIEMENS being informed about the transaction whichever is
later - free of charge to acquire all rights and title to or - if and insofar this is not legally possible - a world-wide, sub-licensable, transferable licence in the FIELD to use and exploit, SURGIVISION’s DEVELOPMENT RESULTS relating to the
SOFTWARE and/or CATHETER TECHNOLOGY and/or PERIPHERAL TECHNOLOGY. If SIEMENS exercises such option, (i) SIEMENS is additionally granted a non-exclusive, world-wide, sublicensable, non-transferable licence in the FIELD to use any BACKGROUND
PATENTS necessary for the use and exploitation of the SOFTWARE and/or CATHETER TECHNOLOGY and/or PERIPHERAL TECHNOLOGY, and (ii) to the extent SIEMENS acquires all rights and title to SURGIVISION’s DEVELOPMENT RESULTS, SIEMENS hereby
grants to SURGIVISION an exclusive, fully paid, world-wide, sublicensable, non-transferable license under such DEVELOPMENT RESULTS in all fields other than the FIELD. Insofar as the DEVELOPMENT RESULTS relate to SOFTWARE, (ii) is not
applicable. Following the exercise of the option, SIEMENS shall no longer be bound by the exclusivity provisions according to Section 9. 

 In return for the aforementioned transfer of title and/or grant of rights following SIEMENS exercise of the option, SIEMENS agrees to pay royalties to SURGIVISION of five percent (5%) of the NET SALES of
CATHETER TECHNOLOGY and/or PERIPHERAL TECHNOLOGY, beginning with market launch of such CATHETER TECHNOLOGY or PERIPHERAL TECHNOLOGY, provided, however, that CATHETER TECHNOLOGY and/or PERIPHERAL TECHNOLOGY contain SURGIVISION DEVELOPMENT RESULTS or
BACKGROUND PATENTS. The five percent (5%) royalty of the NET SALES does only refer to such NET SALES of CATHETER TECHNOLOGY or PERIPHERAL 

  
 29 of 40

 
TECHNOLOGY individual items (e.g. individual catheters or peripheral technology items) that contain SURGIVISION DEVELOPMENT RESULTS or BACKGROUND PATENTS. Payment of such royalties is limited to
the scope of protection of the respective intellectual property rights. “NET SALES” shall mean gross revenue from sales by SIEMENS and/or SIEMENS’ AFFILIATES, SIEMENS’ distributors and other third parties sublicensing the
aforementioned rights from SIEMENS, without value-added, consumption or other taxes imposed on the transaction. If SIEMENS exercises the option described in this Section 17.3, the fifth (5.) paragraph of Section 2.8 shall apply
analogously. 
  

	17.4	 If a CHANGE OF CONTROL occurs involving an INDIRECT COMPETITOR and SIEMENS thereafter terminates this Agreement, or thereafter SIEMENS terminates
the exclusivity, according to Sections 3.10 or 15.3.1(iii) or 15.3.2(i) or 15.3.2(ii) or 15.3.2(iv) or 15.3.2(v) or 15.3.2(vi), SURGIVISION (including any successor in interest to SURGIVISION) shall pay to SIEMENS the amount equal to two million
(2,000,000) US $ eight (8) weeks after such termination of the Agreement or the exclusivity. 

  

	18.	 Arbitration 

  

	18.1.	 Any differences or disputes arising from this Agreement or from agreements regarding its performance shall be settled by an amicable effort on the
part of both PARTIES to the Agreement. An attempt to arrive at a settlement shall be deemed to have failed as soon as one of the PARTIES to the Agreement so notifies the other PARTY in writing. 

 

	18.2.	 If an attempt of settlement has failed, the disputes shall be finally settled under the Rules of Conciliation and Arbitration of the International
Chamber of Commerce in Paris (the “Rules”) by three arbitrators appointed in accordance with the Rules. The place of arbitration shall be Munich, Germany. The procedural law of this place shall apply where the Rules are silent.

  

	18.3.	 The arbitration procedures shall be held in the English language. The arbitral tribunal shall decide on the matter of costs of the arbitration.

  

	19.	 Substantive Law 

 All disputes shall be settled in accordance with the provisions of this Agreement and all other agreements regarding its performance, otherwise in accordance with the substantive law in force in Germany,
without reference to conflict of law rules. This Agreement will be executed in the English language, and the English version shall prevail if there is a dispute regarding the interpretation of a translated copy of this Agreement. 

 

	20.	 Miscellaneous 

  

	20.1.	 This Agreement together with its annexes and any regulation being based on this Agreement is the PARTIES’ entire agreement relating to the
subject matter herein. It 

  
 30 of 40

	 	 
supersedes all prior or contemporaneous oral or written communications, proposals and representations with respect to its subject matter. 

 

	20.2.	 This Agreement may not be released, discharged, abandoned, changed or modified in any manner, except
by an instrument in writing signed on behalf of each of the PARTIES hereto by their duly authorized representatives. 

  

	20.3.	 Unless otherwise agreed upon or provided in this Agreement, neither PARTY shall, without the prior
written consent of the other, transfer or assign to third parties this Agreement or any rights and obligations arising therefrom, except that SURGIVISION may assign this Agreement in connection with a CHANGE OF CONTROL transaction (subject to the
provisions of Section 17). Consent hereto shall not be unreasonably withheld. However, AFFILIATES of SIEMENS or SURGIVISION shall not be regarded as third parties hereunder. 

 

	20.4.	 Failure of a PARTY to enforce at any time any of the provisions of this Agreement shall in no way be
construed to be a waiver of any such provision, nor in any way to affect the validity of this Agreement or any part thereof or the right of any PARTY thereafter to enforce each and every such provision. No waiver of any breach of this Agreement
shall be held to be a waiver of any other or subsequent breach. 

  

	20.5.	 All notices or other communications required or permitted hereunder with regard to the
interpretation, validity etc. of the Agreement shall be in writing and shall be given by certified mail addressed, 

 if to SURGIVISION, to: 
 Kim Jenkins 

SurgiVision, Inc. 
 One Commerce Square 
 Suite 2550 

Memphis, TN (US) 38103 
 with a copy to: 
 Oscar Thomas 

SurgiVision, Inc. 
 One Commerce Square 
 Suite 2550 

Memphis, TN (US) 38103 
 and, if to SIEMENS, to: 
 Siemens Aktiengesellschaft 

Healthcare Sector 
 Imaging & IT Division - MR Business Unit 
 Alle am
Rothelheimpark 2 
 91052 Erlangen 

  
 31 of 40

 or to such other address that the PARTIES might identify to each other for
this purpose and with reference to this Agreement. 
  

	20.6.	 Except otherwise agreed herein, no PARTY hereto shall issue any press release or public announcement or otherwise divulge the existence of this
Agreement or the transactions contemplated hereby without the prior approval of the other PARTY hereto. 

  

	20.7.	 This Agreement shall be binding upon and insure to the benefit of the PARTIES hereto and the successors or permitted assigns of the PARTIES hereto.

  

	20.8.	 Titles and headings to Sections herein are inserted for the convenience or reference only and are not intended to be a part of or to affect the
meaning or interpretation of this Agreement. 

  

	20.9.	 This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement.

 IN WITNESS WHEREOF, the PARTIES hereto have caused this agreement to be executed by their duly authorized
representatives: 
  

					
	 place, date
	 		 	 place, date

	 SURGIVISION
	 		 	 Siemens Aktiengesellschaft

		 		 	 Healthcare Sector

			
	  Kim Jenkins, CEO
	 		 	  Waller Maerfendorfer, CEO H/M MR

	  Name, Function
	 		 	  Name, Function

			
	  /s/ Kim Jenkins
	 		 	  /s/ Waller Maerfendorfer

	  Signature
	 		 	  Signature

			
		 		 	  Holger Liebel, CFO H/M MR

		 		 	  Name, Function

			
		 		 	  /s/ Holger Liebel

		 		 	  Signature

  
 32 of 40

 ANNEX 1 CATHETER TECHNOLOGY DEVELOPMENT 

SURGIVISION shall develop one prototype [***] that includes [***], and one prototype [***] (as described in ANNEX 2). The two prototype
catheters shall be provided by SURGIVISION to SIEMENS by [***] (consistent with the dependency described in Prototype Phase 3 as described in detail in ANNEX 3). 
 SURGIVISION shall develop one final Prototype [***]* (one each) (“final” meaning in final development stage, so that further changes will not influence the implementation / functionality of the
SOFTWARE). The final Prototype [***] shall be provided by SURGIVISION to SIEMENS by [***] (consistent with the dependency described in Prototype Phase 6A of the Development Milestones as described in detail in ANNEX 3). 

SURGIVISION shall develop the final [***]*. The final [***] shall be provided by SURGIVISION to SIEMENS by [***] (or [***]**) (consistent
with the dependencies described in Prototype Phase 9A of the Development Milestones as in ANNEX 3). 
 SURGIVISION shall develop
the Final [***] and provide it to SIEMENS by a date that is [***]** (consistent with the dependencies described in Prototype Phase 9A of the Development Milestones attached in ANNEX 3). 

SURGIVISION shall provide all catheters, equipment and RF room modifications according to final specifications as described in ANNEX 2 at
one of the clinical test site by [***]** (consistent with the dependencies described in Prototype Phases 10A of the Development Milestones attached in ANNEX 3). 
 *As described in ANNEX 2 
 **[***] 

***Assumed start of project 15 May 2009 — all dates will shift in relation to actual start date. 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant
to a request for confidential treatment. 

  
 33 of 40

 ANNEX 2 Description of PRODUCT 
 [***] 
 [***] Indicates portions of this exhibit that have been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

 [***] 
 [***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment. 

  
 34 through 40 of 40

 ANNEX 3 DEVELOPMENT MILESTONES 

[***] 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant
to a request for confidential treatment. 

  
 41 of 40 

 [***] 
 ANNEX 4 LOANED EQUIPMENT (SIEMENS to SURGIVISION) 
 Hardware 

— Coil Connectors 

Software 
 —
Prototype versions of SOFTWARE as available 
 — XIP development environment 

ANNEX 5 Loan Conditions (SIEMENS to SURGIVISION) 
 1.  The delivery of the LOANED ITEMS to the installation site, installation, initial operation, possible dismantling and return of the loaned items to SIEMENS shall be performed by SIEMENS at its own
expense. Taking the necessary measures, if any, for pre-installation preparations or post-removal restoration remains the responsibility of SURGIVISION. Changing the location of the LOANED ITEMS or connecting other equipment to them shall be
conditional on SIEMENS ‘ prior consent, regardless of and without prejudice to the requirements of the laws on medical devices and other statutory regulations. SURGIVISION agrees to use the LOANED ITEMS in the proper manner and with appropriate
care, pursuant to the instructions set forth in the user manuals. 
 2.  Should a third party, in connection with the loan or
the use of LOANED ITEMS by SURGIVISION under the Agreement, advance justified claims arising out of industrial property rights, then SIEMENS shall have the right to terminate the loan and/or use of such LOANED ITEMS under this Agreement at any time
with immediate effect. 
 3.  SURGIVISION shall be responsible for complying with the relevant radiation protection regulations
where applicable. SURGIVISION will also be responsible for obtaining any licenses and other approvals which may be required for the use or operation of the LOANED ITEMS in its facility. 

[***] Indicates portions of this exhibit that have been omitted and filed separately with the Securities and Exchange Commission pursuant
to a request for confidential treatment.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00197-of-00352.parquet"}]]